Document:

Series E. Convertible Preferred Stock

 Exhibit 4.10 
  
 ACCENTIA, INC. 
  
 SERIES E CONVERTIBLE PREFERRED STOCK 
  
 PURCHASE AGREEMENT 
  
 THIS SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE
AGREEMENT (this “Agreement”) is made as of April 15, 2004, by and between ACCENTIA, INC., a Florida corporation having its principal office at 5310
Cypress Center Drive, Suite 101, Tampa, FL 33609 (the “Company”), and Ronald E. Osman whose office is located at 6530 Moake School Rd. Marion, II 62959 (Osman). 
  
 RECITALS 
  
 WHEREAS, the Company has authorized the sale and issuance at Closing of an aggregate of 2,500,000 shares of its
Series E Convertible Preferred Stock, $1.00 par value per share (the “Shares”); 
  
 WHEREAS, the Company has authorized the issuance of warrants (collectively and as further defined below, the
“Warrants”) for the purchase of up to 5,000,000 additional shares of Series E Convertible Preferred Stock; 
  
 WHEREAS, Osman desires to purchase the Shares and receive the Warrants on the terms and conditions set forth herein;
and 
  
 WHEREAS, the Company
desires to issue and sell the Shares and the Warrants to Osman on the terms and conditions set forth herein. 
  
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises, representations,
warranties, and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  
 AGREEMENT 
  
 1. PURCHASE AND SALE OF
SHARES; ISSUANCE OF WARRANTS. 
  
 1.1 Sale and Issuance of Shares; Issuance of Warrants. 
  
 (a) The Amended and Restated Articles of Incorporation of the Company authorizing shares of Series E Convertible Preferred Stock is
attached hereto as Exhibit A (the “Restated Charter”). 
  
 (b) Subject to the terms and conditions of this Agreement, Osman agrees to purchase, and the Company agrees to sell and issue to
Osman, the Shares at a purchase price of $1.00 per Share (the “Purchase Price”). 
  
 (c) Subject to the terms and conditions of this Agreement, the Company agrees to issue to Osman, and Osman agrees to receive from
the Company, the Warrants, which 

  

 1. 

 
consist of the following: (i) one Class A Warrant, in the form attached hereto as Exhibit B, entitling Osman, at any time for a period of twelve (12)
months following the Closing, in the exercise of its discretion, to purchase up to 2,500,000 shares of Series E Convertible Preferred Stock for $1.00 per share (the “Class A Warrant”), and (ii) one Class B Warrant, in the
form attached hereto as Exhibit C, entitling Osman at any time after the full exercise of the Class A Warrant and within twenty-four (24) months following the Closing, in the exercise of its discretion, to purchase up to an additional
2,500,000 shares of Series E Convertible Preferred Stock for $1.00 per share (the “Class B Warrant”). The Class A Warrant and the Class B Warrant are hereinafter collectively referred to as the
“Warrants” and the shares of Series E Convertible Preferred Stock issuable pursuant to the Warrants are hereinafter collectively referred to as the “Warrant Shares”. 
  
 (d) The total amount of Common Stock and other
securities issuable upon the conversion of the Shares and the Warrant Shares is hereinafter referred to as the “Conversion Stock”. The Shares, Warrant Shares and Conversion Stock are hereinafter collectively referred to as
the “Securities”. 
  
 1.2
Closing. The purchase and sale of the Shares and the issuance of the Warrants shall take place at the offices of the Company in Tampa, Florida,, on April             ,
2004 or at such other date, time and place as the Company and Osman mutually agree upon (which date is designated the “Closing Date” and which time and place are designated as the “Closing”). At the
Closing, the Company shall deliver to Osman (i) a certificate representing the Shares, (ii) the Class A Warrant, and (iii) the Class B Warrant, and Osman shall deliver to the Company, as payment in full for the Shares and the Warrants being
purchased at Closing, immediately payable funds in the aggregate amount of the Purchase Price for the Shares by wire transfer payable to the order of the Company. 
  
 2. REPRESENTATIONS AND WARRANTIES OF THE
COMPANY. The Company hereby represents and warrants to Osman that, on the date hereof and as of the Closing, except as set forth on a Schedule of Exceptions attached hereto as Exhibit D and delivered to Osman on the date
hereof (the “Schedule of Exceptions”), which exceptions shall be deemed to be representations and warranties as if made hereunder: 
  
 2.1 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Florida. The Company has all requisite corporate power and authority to own and operate its properties and to carry on its business as presently conducted and as proposed to be conducted. The Company has all requisite legal
and corporate power (i) to execute and deliver this Agreement and all listed exhibits hereto, (ii) to sell and issue the Shares hereunder, (iii) to issue the Warrants hereunder, (iv) to issue the Conversion Stock, and (v) to carry out and perform
its obligations under the terms of this Agreement. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on its business, operations,
assets, liabilities, properties, prospects, condition or affairs, financially or otherwise. 
  

 2. 

 2.2 Capitalization. Immediately prior to the Closing, the authorized capital of the Company
consists of: 
  
 (a) 95,000,000 shares of
Preferred Stock (the “Preferred Stock”), of which (i) 10,000,000 shares have been designated Series A Convertible Preferred Stock (the “Series A Stock”), (ii) 30,000,000 shares have been designated
Series B Convertible Preferred Stock, (the “Series B Stock”), (iii) 10,000,000 shares have been designated Series C Convertible Preferred Stock (the “Series C Stock”), (iv) 15,000,000 shares have been
designated Series D Convertible Preferred Stock (the “Series D Stock”), and (v) 30,000,000 shares have been designated Series E Convertible Preferred Stock (the “Series E Stock”). Immediately prior to
the Closing (without taking into account such Closing), 3,233,000 shares of Series A Stock are issued and outstanding, 8,074,263 shares of Series B Stock are issued and outstanding, 7,500,000 shares of Series C Stock are issued and outstanding, and
11,790,486 shares of Series D Stock are issued and outstanding, 9,289,000 shares of Series E Stock (and warrants to purchase an additional 10,000,000 shares of Series E Stock granted to PPD) are issued and outstanding. The rights, preferences,
privileges and restrictions of the Preferred Stock will be as stated in the Restated Charter. 
  
 (b) 300,000,000 shares of Common Stock (the “Common Stock”), of which 10,264,200 shares are issued and
outstanding. 
  
 Except as provided herein or in the Schedule of Exceptions, and
except for the conversion privileges of the Preferred Stock, there are no other outstanding options, warrants, rights (including conversion rights, preemptive rights, co-sale rights, rights of first refusal or other similar rights) or agreements for
the purchase or acquisition from the Company of any shares of its capital stock. Approximately 1,496,851 shares of Common Stock and approximately 2,812 shares of Series D Convertible Preferred Stock remain available for future issuance under the
Company’s stock option plans. 
  
 2.3
Subsidiaries. The Company has the following subsidiaries (collectively, the “Subsidiaries”, and each a “Subsidiary”): The Analytica Group, Inc. (“Analytica”), TEAMM
Pharmaceuticals, Inc. (“TEAMM”), Accent Rx, Inc. (“Accent Rx”), BioVest International, Inc.(approximately 81% owned) (“BioVest”), and Imor-Analytica GmbH
(“IA”). Other than the Subsidiaries noted above, the Company does not presently own or control, directly or indirectly, any interest in any other corporation, association, or other business entity, and except as provided on
the Schedule of Exceptions, the Subsidiaries are wholly owned by the Company. Analytica, TEAMM, and Accent Rx are corporations duly organized, validly existing and in good standing under the laws of the State of Florida. BioVest is a corporation
duly organized, validly existing and in good standing under the laws of the State of Delaware. IA is a private limited company duly organized, validly existing and in good standing under the laws of Germany. The Subsidiaries have all requisite
corporate power and authority to own and operate their properties and to carry on their businesses as presently conducted and as proposed to be conducted. The Subsidiaries are duly qualified to transact business and are in good standing in each
jurisdiction in which the failure to so qualify would have a material adverse effect on their business, operations, assets, liabilities, properties, prospects, condition or affairs, financially or otherwise. 
  
 2.4 Authorization. Prior to Closing, all corporate action on
the part of the Company, its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of this Agreement, the Investors Rights Agreement and the other exhibits attached hereto (ii) the 

  

 3. 

 
performance of all obligations of the Company hereunder and thereunder, and (iii) the authorization, issuance (or reservation for issuance), sale and
delivery of the Shares, the Warrants and the Conversion Stock has been taken or will be taken prior to the Closing, and this Agreement constitutes valid and legally binding obligations of the Company, enforceable in accordance with their terms,
subject as to enforceability only to applicable bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium and similar laws affecting the enforcement of creditors’ rights generally and general principles of equity. 
  
 2.5 Valid Issuance of Preferred and Common Stock. 

 
 (a) The Shares, when issued, sold and delivered in
accordance with the terms hereof for the consideration expressed herein, will be duly and validly issued, fully paid, nonassessable and free of any liens or encumbrances and free of restrictions on transfer other than restrictions on transfer under
this Agreement and applicable state and federal securities laws. Based in part upon the representations of Osman in this Agreement, the Shares will be issued in compliance with all applicable federal and state securities laws. The Conversion Stock
has been duly and validly reserved for issuance and, upon issuance in accordance with the terms of the Company’s Restated Charter, shall be duly and validly issued, fully paid, nonassessable and free of restrictions on transfer other than
restrictions on transfer under this Agreement and applicable state and federal securities laws, and issued in compliance with all applicable securities laws, as presently in effect, of the United States and each of the states whose securities laws
govern the issuance of any of the Shares hereunder. The terms of the Shares as set forth in the Restated Charter are legally binding obligations of the Company and are enforceable in accordance with their terms. No documentary stamp tax, or similar
tax, is or will be imposed on the Company’s issuance of the securities issued or issuable in connection with this Agreement or the transactions contemplated hereunder under any state or local government or authority. 
  
 (b) The outstanding shares of Common Stock and
Preferred Stock are all duly and validly authorized and issued, fully paid and nonassessable and were issued in compliance with all applicable federal and state securities laws. 
  
 (c) The Warrants, when issued and delivered in accordance with the terms hereof, will be duly and
validly issued, fully paid, nonassessable and free of restrictions on transfer other than restrictions on transfer under this Agreement, the Warrants and applicable state and federal securities laws. 
  
 2.6 Governmental Consents. No consent, approval, order or
authorization of, or registration, qualification, designation, declaration or filing with, any federal, state, local or provincial governmental authority on the part of the Company is required in connection with the consummation of the transactions
contemplated by this Agreement, except for qualification (or taking such action as may be necessary to secure an exemption from qualification, if available) of the offer and sale of the Securities under applicable federal securities laws and Blue
Sky laws, which filings and qualifications, if required, will be accomplished in a timely manner. 
  
 2.7 Litigation. With the exception of with TXRX regarding an approximately $300,000 vendor claim against a subsidiary, there is no
action, suit, proceeding or investigation pending or threatened against the Company or any Subsidiary, which questions the validity of 

  

 4. 

 
this Agreement or the right of the Company to enter into this Agreement, or to consummate the transactions contemplated hereby, or which might result, either
individually or in the aggregate, in any material adverse changes in the business, operations, assets, liabilities, properties, prospects, condition or affairs, financially or otherwise, of the Company or any Subsidiary or any change in the current
equity ownership of the Company or any Subsidiary, nor is the Company aware that there is any basis for the foregoing. The foregoing includes, without limitation, actions pending or threatened (or any basis therefor known to the Company) involving
the prior employment of any of the employees of the Company or any Subsidiary, their use in connection with the business of the Company or any Subsidiary of any information or techniques allegedly proprietary to any of the former employers, or their
obligations under any agreements with prior employers. Neither the Company nor any Subsidiary is a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is
no action, suit, proceeding or investigation by the Company or any Subsidiary currently pending or which the Company or any Subsidiary intends to initiate. 
  
 2.8 Proprietary Information and Inventions Agreements. To the best of the Company’s knowledge, each current and former key employee and
officer of the Company and its Subsidiaries has executed a proprietary information and inventions agreement, a form of which has been made available to Osman, and no exceptions have been taken by any such employee or officer to the terms of such
agreement The Company and its Subsidiaries, after reasonable investigation, are not aware that any of their current or former employees or consultants is in violation thereof, and the Company and its Subsidiaries will use their best efforts
to prevent any such violation. To the best of the Company’s knowledge, all present consultants to or vendors of the Company and its Subsidiaries with access to confidential information of the Company or its Subsidiaries are parties to a written
agreement substantially similar to the proprietary information and inventions agreement under which, among other things, each such consultant or vendor is obligated to maintain the confidentiality of information of the Company and its Subsidiaries.

  
 2.9 Permits. To the best of the Company’s
knowledge, the Company and its Subsidiaries have all franchises, permits, licenses and other similar authority (collectively, “Permits”) necessary for the conduct of their businesses as now being conducted and as proposed to
be conducted, the lack of which could materially and adversely affect the business, operations, assets, liabilities, properties, prospects, condition or affairs, financially or otherwise, of the Company or its Subsidiaries. Neither the Company nor
any Subsidiary is in default in any material respect under any such Permits, nor is either of them in violation of any applicable statute, rule, regulation, order or restriction of any domestic or foreign government or any instrumentality or agency
thereof in respect of the conduct of its business or the ownership of its properties which violation would materially and adversely affect the business, operations, assets, liabilities, properties, prospects, condition or affairs, financially or
otherwise, of the Company or any Subsidiary. 
  

 5. 

 2.10 Patents, Copyrights and Trademarks. 
  
 (a) For purposes of this Agreement,
“Intellectual Property” means the following items of intangible property: 
  
 (i) Patents, whether in the form of utility patents or design patents and all pending applications for such patents; 
  
 (ii) Trademarks, trade names, service marks, designs,
logos, trade dress, and trade styles, whether or not registered, and all pending applications for registration of the same; 
  
 (iii) Copyrights, whether or not registered, and all pending applications for registration of the same; 
  
 (iv) Inventions, research records, trade secrets,
confidential information, product designs, engineering specifications and drawings, technical information, formulae, customer lists, supplier lists and market analyses; and 
  
 (v) Computer programs, including, without limitation, computer programs embodied in semiconductor
chips or otherwise embodied, and related flow-charts, programmer notes, updates and data, whether in object or source code form. 
  
 (b) The Company and its Subsidiaries possess all of the Intellectual Property necessary to enable the operation of their businesses
as now being conducted and as proposed to be conducted. 
  
 (c) The Company and its Subsidiaries have good, valid, subsisting, unexpired and enforceable title (free and clear of all liens, mortgages, encumbrances, security interests, claims, charges or pledges
(individually, a “Lien” and collectively, “Liens”), assignments, options to purchase and rights or equitable interests of others of any nature whatsoever or otherwise possesses adequate and exclusive
rights to use) to all of the Intellectual Property necessary to enable operation of their businesses as now being conducted and as proposed to be conducted. The Company is not currently aware of any Intellectual Property owned by any third party
that is needed by the Company or any Subsidiary to conduct their businesses as currently conducted or contemplated. The Company and its Subsidiaries have taken reasonable security measures, including measures against unauthorized disclosure, to
protect the secrecy, confidentiality, and value of their trade secrets and other technical information. No employee, director or stockholder of the Company or any Subsidiary, or employer of any such employee, has any rights to processes, systems and
techniques used or contemplated to be used by the Company or its Subsidiaries. 
  
 (d) To the best of the Company’s knowledge, no Intellectual Property, used or proposed to be used in the businesses of the
Company and its Subsidiaries as currently conducted or contemplated, has infringed or will infringe upon any intellectual property rights of others and the use of such Intellectual Property in the businesses of the Company and its Subsidiaries, as
currently conducted or contemplated, will not constitute an infringement, misappropriation or misuse of any intellectual property rights of any third party. No person has asserted or, to the 

  

 6. 

 
Company’s knowledge, has the right to assert any claim regarding the use of, or challenging or questioning the Company’s or any Subsidiary’s
right or title in, any of the Intellectual Property. 
  
 (e) Other than granted, issued or entered into in the ordinary course of business, there are no outstanding options, licenses, or agreements of any kind relating to the Intellectual Property of the Company or any Subsidiary. Other
than granted, issued or entered into in the ordinary course of business, neither the Company nor any Subsidiary is bound by or a party to any options, licenses or agreements of any kind with respect to Intellectual Property of any other person or
entity. 
  
 (f) The Company is not aware
that any of the Company’s or any Subsidiary’s employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or
administrative agency, that would interfere with the use of such employee’s best efforts to promote the interests of the Company and its Subsidiaries or that would conflict with the Company’s or any Subsidiary’s business as proposed
to be conducted immediately following the Closing. Neither the execution nor delivery of this Agreement, nor the carrying on of the Company’s or any Subsidiary’s business by the employees of the Company or any Subsidiary, nor the conduct
of the Company’s or any Subsidiary’s business as proposed immediately following the Closing, will, to the Company’s knowledge, conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default
under, any contract, covenant or instrument under which any such employee is now obligated. The Company does not believe it is or will be necessary to utilize any inventions of any of the Company’s or its Subsidiary’s employees (or people
it currently intends to hire) made prior to their employment by the Company or the Subsidiaries. 
  
 2.11 Compliance with Other Instruments. 
  
 (a) Neither the Company nor any Subsidiary is in violation or default of any provisions of its Charter or Bylaws, each as amended
and in effect on and as of the Closing, or of any instrument, judgment, order, writ, decree or contract to which it is a party or by which it is bound or, to its knowledge, of any provision of any federal or state statute, rule or regulation
applicable to the Company or its Subsidiaries. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby and thereby will not result in any violation, which could result in a material
adverse effect on the business, operations, assets, liabilities, properties, prospects, condition or affairs, financially or otherwise, of the Company or any Subsidiary or be in conflict with or constitute, with or without the passage of time and
giving of notice, either a default under any such provision, instrument, judgment, order, writ, decree or contract or an event which results in the creation of any Lien upon any assets of the Company or its Subsidiaries. 
  
 (b) To the best of the Company’s knowledge, the
Company and its Subsidiaries have avoided every condition, and have not performed any act, the occurrence of which would result in the Company’s or any Subsidiary’s loss of any right granted under any license, distribution or other
agreement in effect as of the Closing. 
  

 7. 

 2.12 Agreements; Action. 
  
 (a) Neither the Company nor any Subsidiary is a party to or is bound by any contract, agreement or
instrument, or subject to any restriction under its Charter or Bylaws, each as amended on and through the date of Closing, which materially adversely affects its business, operations, assets, liabilities, properties, prospects, condition or affairs,
financially or otherwise, as such business is now conducted and as proposed to be conducted immediately following the Closing. 
  
 (b) Other than the sale of certain assets of Accent Rx to Chronimed Inc. and the potential sale of Preferred Stock pursuant to such
transaction, neither the Company nor any Subsidiary has engaged in the past three (3) months in any discussion (i) with any representative of any corporation or corporations (or other entities) regarding the consolidation or merger of the Company or
any Subsidiary with or into any such corporation or corporations, (ii) with any corporation, partnership, association or other business entity or any individual regarding the sale, conveyance or disposition of all or substantially all of the assets
of the Company or any Subsidiary, or a transaction or series of related transactions in which more than fifty percent (50%) of the voting power of the Company or any Subsidiary is disposed of, or (iii) regarding any other form of acquisition,
liquidation, dissolution or winding up, of the Company or any Subsidiary. 
  
 2.13 Disclosure. The Company has fully provided Osman with all the information, which Osman has requested for deciding whether to purchase the Shares and all information, which the Company believes, is
reasonably necessary to enable Osman to make such decision or which could materially and adversely affect the business, operations, assets, liabilities, properties, prospects, conditions or affairs, financially or otherwise, of the Company or its
Subsidiaries. Neither this Agreement, nor any other written statements, exhibits or certificates made or delivered in connection herewith or therewith, when taken as a whole, contains any untrue statement of a material fact or omits to state a
material fact necessary to make the statements herein or therein not misleading which has not been, prior to the Closing, corrected or amended. 
  
 2.14 Registration Rights. Except as granted to other holders of Series E Convertible Preferred Stock or as disclosed in the Schedule of
Exceptions, neither the Company nor any Subsidiary has granted or agreed to grant any registration rights, including piggyback rights, to any person or entity. 
  

2.15 Title to Property and Assets. The Company and its Subsidiaries have good and marketable title to all of their material properties
and assets owned by them and own such property and assets free and clear of all Liens, except as otherwise set forth on the Company’s Financial Statements delivered to Osman or listed on Schedule 2.15 of the Schedule of Exceptions. With respect
to the property and assets they lease, the Company and its Subsidiaries are in compliance with such leases and, to the Company’s knowledge, holds a valid leasehold interest free of any Liens. To the Company’s knowledge, there exists no
default or other encumbrance or condition that would result in a default or termination under any of their leases. 
  

 8. 

 2.16 Labor Agreements and Actions. Neither the Company nor any Subsidiary is bound by or
subject to (and none of its assets or properties is bound by or subject to) any written or oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has requested or, to the knowledge of the Company, has
sought to represent any of the employees, representatives or agents of the Company or its Subsidiaries. There is no strike or other labor dispute involving the Company or its Subsidiaries pending, or to the knowledge of the Company threatened, which
could have a material adverse effect on the assets, properties, financial condition, operating results, or business of the Company and its Subsidiaries, nor is the Company aware of any labor organization activity involving the employees of the
Company or its Subsidiaries. 
  
 2.17 Obligations to
Related Parties. Other than set forth in the Financial Statements (specifically identified as such therein) or on Schedule 2.17 of the Schedule of Exceptions, there are no obligations of the Company or any Subsidiary to officers, directors,
stockholders, or employees of the Company or any Subsidiary other than (i) for payment of salary for services rendered, (ii) reimbursement for reasonable expenses incurred on behalf of the Company or its Subsidiaries and (iii) for other standard
employee benefits made generally available to all employees (including stock option agreements outstanding under any stock option plan approved by the Board of Directors of the Company). None of the officers, members of the Board of Directors or
stockholders of the Company or any Subsidiary, or any members of their immediate families, are indebted to the Company or any Subsidiary or have any direct or indirect ownership interest in any firm or corporation with which the Company or any
Subsidiary is affiliated or with which the Company or any Subsidiary has a business relationship, or any firm or corporation which competes with the Company or any Subsidiary, except that officers, directors and/or stockholders of the Company and
its Subsidiaries may own stock in publicly traded companies which may compete with the Company or any Subsidiary. No officer, director or stockholder, or any member of their immediate families, is, directly or indirectly, interested in any material
contract with the Company or any Subsidiary (other than such contracts as relate to any such person’s ownership of capital stock or other securities of the Company). Neither the Company nor any Subsidiary is a guarantor or indemnitor of any
indebtedness of any other person, firm or corporation. Any employee plans set forth in the Schedule of Exceptions are in compliance in all material respects with all applicable laws. 
  
 2.18 Employee Relations. The Company believes that its relations with the key employees of the Company and its
Subsidiaries are satisfactory, and that no employee has violated any term of any employment contract, patent disclosure agreement, or any other contract or agreement with the Company or any Subsidiary. The Company is not aware that any of the
officers or key employees of the Company or its Subsidiaries, or that any group of key employees, intends to terminate their employment with the Company or any Subsidiary, nor does the Company or any Subsidiary have a present intention to terminate
the employment of any of the foregoing. The Company and each Subsidiary has complied in all material respects with all applicable state, federal and foreign equal employment opportunity laws and with other laws related to employment. 
  
 2.19 Environmental and Safety Laws. To the best of the
Company’s knowledge, the Company and its Subsidiaries are not in violation of any applicable statute, law or regulation relating to the environment or occupational health and safety, and to the Company’s knowledge, 

  

 9. 

 
no material expenditures are or shall be required in order to comply with any such existing statute, law or regulation. 
  
 2.20 Private Placement. Based in part on representations of
Osman, the offer, sale and issuance of the Securities as contemplated by this Agreement are, and will be, exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), and have
been registered or qualified (or are exempt from registration and qualification under the registration, permit or qualification requirements of all applicable state securities laws) and neither the Company nor any authorized agent acting on its
behalf will take any action hereafter that would cause the loss of such exemption. 
  
 2.21 Taxes. All federal, state, local and foreign tax returns required to be filed by the Company and its Subsidiaries have been timely filed, or if not yet filed, extensions of the filing dates have
been properly granted and have not expired. All taxes, assessments, fees and other governmental charges upon the Company or any Subsidiary, or upon any of its respective properties, income or franchises, have been paid or adequate reserves therefor
have been set up if any of such taxes are being contested in good faith. Neither the Company nor any Subsidiary has any pending or, to the knowledge of the Company, threatened tax audit. 
  
 2.22 No Defaults, Violations or Conflicts. Neither the Company nor any Subsidiary is in violation or default
of any term or provision of its Charter, Bylaws, each as amended on and through the date of Closing, or of any instrument, judgment, order, writ, decree, license, permit or contract to which it is a party, by which it is bound or to which its
property is subject, or of any provision of state, federal or foreign statute, rule or regulation applicable to the Company or the Subsidiaries, which violation or violations, either individually or in the aggregate, would materially and adversely
affect the business, assets, liabilities, financial condition, operations or prospects of the Company and its Subsidiaries, taken as a whole. The Company and its Subsidiaries have avoided every condition, and has not performed any act, the
occurrence of which would result in the loss by them of any right granted under any license, distribution or other agreement, which is necessary for the conduct of their businesses as now being conducted by them. 
  
 2.23 Insurance. The Company and its Subsidiaries have obtained
insurance that is typical for companies similarly situated in similar businesses. The Company is not aware of any pending or threatened claims against the Company or any Subsidiary that could materially and adversely affect the business, assets,
liabilities, financial condition, operations or prospects of the Company or its Subsidiaries, taken as a whole. 
  
 2.24 Brokers and Finders. No agent, broker, investment banker or other firm or person acting on behalf or under the authority of the Company
or any Subsidiary is or shall be entitled to any broker’s or finder’s fee or any other commission or similar fee from the Company or any Subsidiary in connection with any of the transactions contemplated by this Agreement. 
  
 2.25 Investment Company Act of 1940. The Company is not an
“investment company” or a company “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940, as amended (the “1940 Act”). 
  

 10. 

 2.26 Stockholder List and Agreements. Attached as Schedule 2.26 of the Schedule of
Exceptions is a true and complete list of the stockholders of the Company, showing the number of shares of Common Stock, Preferred Stock or other securities of the Company held by each stockholder as of the date of this Agreement and the
consideration paid to the Company, if any, for such shares. Except as contemplated by this Agreement, and as set forth in the Company’s Restated Charter or Schedule 2.26 of the Schedule of Exceptions, there are no agreements, written or oral,
between the Company and any holder of its capital stock, or, to the best knowledge of the Company, among any holders of its capital stock, relating to the acquisition (including, without limitation, rights of first refusal or preemptive rights),
disposition or voting of the capital stock of the Company. 
  
 2.27 Liabilities. Except as disclosed in Schedule 2.27 of the Schedule of Exceptions and the Financial Statements (as hereinafter defined), the Company does not have, as of the date of this Agreement, any liability of any
type, whether absolute, accrued or contingent exceeding, individually, $100,000. 
  
 2.28 Financial Statements. The Company has furnished to Osman a complete and correct copy of the consolidated, compiled balance sheet of the Company and the Subsidiaries dated as of September 30, 2003
(the “Balance Sheet Date”) and the related statements of operations, stockholders’ equity and cash flows for the periods then ended (collectively, the “Financial Statements”). The Financial
Statements are complete and correct, are in accordance with the books and records of the Company and present fairly the financial condition and results of operations of the Company and its Subsidiaries, as at the dates and for the periods indicated,
and have been prepared in accordance with United States generally accepted accounting principles consistently applied (“GAAP”), except that the Financial Statements may not be in accordance with GAAP because of the absence of
footnotes normally contained therein and are subject to normal year-end audit adjustments which in the aggregate will not be material. 
  
 2.29 Changes. Since the Balance Sheet Date, there has not been: 
  
 (a) any change (other than the sale of assets by Accent Rx to Chronimed Inc. the purchase of IA, the
$5,000,000 investment in Series E Convertible Preferred Stock by PPD, the $3,000,000 biologics contract deposit with the Company; the distribution agreement with Teamm by McKesson, and the license Agreement between the Company and Mayo Foundation)
in the business, operations, assets, liabilities, properties, prospects, condition or affairs, financially or otherwise, of the Company or any Subsidiary from that reflected in the Financial Statements, except changes in the ordinary course of
business that have not been, in the aggregate, materially adverse; 
  
 (b) any damage, destruction or loss, whether or not covered by insurance, materially and adversely affecting the business, operations, assets, liabilities, properties, prospects, condition or affairs,
financially or otherwise of the Company or any Subsidiary (as such business is presently conducted and as it is proposed to be conducted); 
  
 (c) any waiver by the Company or any Subsidiary of a valuable right or of a material debt owed to it; 
  

 11. 

 (d) any satisfaction or discharge of any lien, claim or encumbrance or payment of
any obligation by the Company or any Subsidiary, except in the ordinary course of business and that is not material to the business, operations, assets, liabilities, properties, prospects, condition or affairs, financially or otherwise of the
Company or any Subsidiary (as such business is presently conducted and as it is proposed to be conducted); 
  
 (e) any material change or amendment to a material contract or arrangement (other than the debt assumption contracts with McKesson
Corporation, true and correct copies of which will be provided to Osman upon request) by which the Company or any Subsidiary, or any of their assets or properties are bound or subject; 
  
 (f) any material change in any compensation arrangement or agreement with any employee, director or
consultant; 
  
 (g) any sale, assignment
or transfer of any patents, trademarks, copyrights, trade secrets or other Intellectual Property; 
  
 (h) any resignation or termination of employment of any key officer of the Company or any Subsidiary; and the Company, to the best
of its knowledge, does not know of the impending resignation or termination of employment of any such officer; 
  
 (i) receipt of notice that there has been a loss of, or material order cancellation by, any major customer of the Company or any
Subsidiary; 
  
 (j) any Lien created by
the Company or any Subsidiary, with respect to any of its material properties or assets, except Liens for taxes not yet due or payable; 
  
 (k) any loans or guarantees made by the Company or any Subsidiary to or for the benefit of their employees, officers or directors,
or any members of their immediate families, other than travel advances and other advances made in the ordinary course of their businesses; 
  
 (l) any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock, or any
direct or indirect redemption, purchase or other acquisition of any of such stock by the Company; 
  
 (m) to the best of the Company’s knowledge, any other event or condition of any character that might materially and adversely
affect the business, operations, assets, liabilities, properties, prospects, condition or affairs, financially or otherwise of the Company or any Subsidiary (as such business is presently conducted and as it is proposed to be conducted); or

  
 (n) any agreement or commitment by the
Company or any Subsidiary to do any of the things described in this Section 2.29. 
  
 2.30 Regulatory Authorities. 
  
 (a) To the best of the Company’s knowledge, the Company and its Subsidiaries have such Permits of governmental or regulatory authorities, including, without limitation, the Food and Drug Administration
(the “FDA”) of the U.S. Department of Health 

  

 12. 

 
and Human Services and/or any committee thereof, as are necessary to own, lease and operate their properties and to conduct their businesses as now conducted
and as currently proposed to be conducted; the Company and its Subsidiaries have fulfilled and performed all their material obligations with respect to the Permits, and no event has occurred that allows, or after notice of lapse of time would allow,
revocation or termination thereof or results in any other impairment of the rights of the holder of any Permit. None of the Permits contains any restriction that is materially burdensome to the Company or its Subsidiaries, taken as a whole.

  
 (b) Except as provided on the Schedule
of Exceptions, the feasibility, pre-clinical, clinical and other studies and tests conducted by or on behalf of or sponsored by the Company and its Subsidiaries or in which the Company or its Subsidiaries or the Company’s or Subsidiary’s
products under development have participated, if any, were and, if still pending, are being conducted in accordance with standard medical and scientific research procedures. The Company has no knowledge of any other studies or tests the results of
which are inconsistent with or otherwise call into question the results of the above-referenced tests. The Company and its Subsidiaries have operated and currently are in compliance in all material respects with all applicable FDA rules, regulations
and policies, and the Company and its Subsidiaries have not received any notices or other correspondence from the FDA or any other governmental agency requiring the termination, suspension or modification of any of the above-referenced feasibility,
pre-clinical or clinical studies or tests. 
  
 3.
REPRESENTATIONS AND WARRANTIES OF OSMAN. Osman hereby represents and warrants to the Company that as of the date hereof and the Closing: 
  
 3.1 Authorization. When executed and delivered by Osman, and
assuming execution and delivery by the Company, this Agreement constitutes valid and legally binding obligations of Osman, enforceable in accordance with its terms, subject as to enforceability only to applicable bankruptcy, insolvency,
reorganization, fraudulent conveyance, moratorium and similar laws affecting the enforcement of creditors’ rights generally and general principles of equity. 
  
 3.2 Purchase Entirely for Own Account. This Agreement is made with Osman in reliance upon Osman’s
representation to the Company, which by Osman’s execution of this Agreement it hereby confirms, that the Securities will be acquired for investment for Osman’s own account, not as a nominee or agent, and not with a view to the resale or
distribution of any part thereof, and that Osman has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, Osman further represents that Osman does not have any contract,
undertaking, agreement or arrangement with any person to sell, transfer or grant participation to such person or to any third person, with respect to any of the Securities. Osman represents that it has full power and authority to enter into this
Agreement. 
  
 3.3 Investment Experience.

  
 (a) Osman is an “accredited
investor” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act; and 
  

 13. 

 (b) Osman is an investor in securities of companies in the development stage and
acknowledges that it is able to protect its interests and bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the
Securities. 
  
 3.4 Restricted Securities. Osman
understands that the Securities are characterized as “restricted securities” under the federal securities laws in as much as they are being acquired from the Company in a transaction not involving a public offering and that under such laws
and applicable regulations such Securities may be resold without registration under the Securities Act only in certain limited circumstances. Osman represents that it is familiar with Rule 144, as presently in effect, and understands the resale
limitations imposed thereby and by the Act. 
  
 3.5 No
Public Market. Osman understands that no public market now exists for any of the securities issued by the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities. 
  
 3.6 Economic Risk. Osman understands that the Company has
limited financial and operating history and that investment in the Company involves substantial risks. Subject to the truth and accuracy of the representations and warranties made by the Company set forth in this Agreement, Osman understands all of
the risks related to the purchase of the Securities. Osman further understands that the purchase of the Securities will be a highly speculative investment. Osman is able, without impairing Osman’s financial condition, to hold the Securities for
an indefinite period of time and to suffer a complete loss of Osman’s investment. 
  
 3.7 Further Limitations on Disposition. Without in any way limiting the representations set forth above, Osman further agrees not to make any disposition of all or any portion of the Securities unless
and until: 
  
 (a) There is then in effect
a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with such registration statement; 
  
 (b) (i) Osman shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed
statement of the circumstances surrounding the proposed disposition, and (ii) if requested by the Company, Osman shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not
require registration of such shares under the Act, provided that the Company will not require opinions of counsel for transactions made pursuant to Rule 144 of such Act; or 
  
 (c) Notwithstanding the provisions of subsections (a) and (b) above, no such registration statement
or opinion of counsel shall be necessary for a transfer by Osman to any assignee of Osman, including any family trust, partnership or limited liability company in which Osman is the trustee, general partner or manager. 
  

 14. 

 3.8 Legends. It is understood that the certificates evidencing the Securities may bear all
of the following legends: 
  
 “THESE SECURITIES HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR AN OPINION OF COUNSEL SATISFACTORY TO
THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.” 
  
 4. CONDITIONS OF OSMAN’S OBLIGATIONS AT THE CLOSING. The obligations of Osman
under Section 1.2 of this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, the waiver of which shall not be effective against Osman unless consented to in writing thereto: 
  
 4.1 Representations and Warranties. The representations and
warranties of the Company contained in Section 2 shall be true on and as of the date of the Closing with the same effect as though such representations and warranties had been made on and as of the date of the Closing. 
  
 4.2 Performance. The Company shall have performed and complied
with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing. 
  

4.3 Satisfaction. All corporate and legal proceedings taken by the Company in connection with the transactions contemplated by this
Agreement and all documents relating to such transactions shall be satisfactory to Osman in the reasonable exercise of its judgment. 
  
 4.4 Compliance Certificate. The Chief Executive Officer, President or a Vice President of the Company shall deliver to Osman a certificate
certifying that the conditions specified in Sections 4.1 and 4.2 have been fulfilled. 
  
 4.5 Blue Sky. The Company shall have obtained all necessary Blue Sky law permits and qualifications, or have the availability of exemptions therefrom, required by any state for the offer and sale of the
Securities. 
  
 4.6 Consents, Permits, and Waivers.
The Company shall have obtained any and all consents, permits and waivers necessary or appropriate for consummation of the transactions contemplated by this Agreement (except for such as may be properly obtained subsequent to the Closing).

  
 4.7 Legal Investment. The sale and issuance of
the Shares and the Warrants to Osman, and the proposed delivery of the Conversion Stock into which the Shares and Warrant Shares may convert, shall be legally permitted by all securities laws and regulations to which Osman and the Company are
subject. 
  
 4.8 Investors’ Rights Agreement.
The Company shall have executed and delivered the Investors’ Rights Agreement substantially in the form attached hereto as Exhibit E. 
  
 4.9 Secretary’s Certificate. There shall have been delivered to Osman a certificate, dated as of the date of Closing hereunder, signed
by the Company’s Secretary or an Assistant 

  

 15. 

 
Secretary and in form and substance reasonably satisfactory to Osman, that shall certify (i) the names of its officers authorized to sign this Agreement, the
certificates for purchased Shares and the other documents, instruments or certificates to be delivered pursuant to this Agreement by the Company or any of its officers, together with true signatures of such officers; (ii) that the copy of the
Restated Charter attached thereto is true, correct and complete; (iii) that the copy of the Bylaws attached thereto is true, correct and complete; and (iv) that the copies of the director and stockholder resolutions attached thereto evidencing the
approval of this Agreement, the issuance of the purchased Shares and Warrants and the other matters contemplated hereby was duly adopted and is in full force and effect. 
  
 5. POST-CLOSING COVENANTS OF THE COMPANY.

  
 5.1 Securities Laws Compliance. Within fifteen (15)
days of the Closing, the Company will file a notice of the sale of the Shares to Osman pursuant to Form D under the Securities Act, and will make any other filings required by the securities, Blue Sky or other applicable laws of any applicable state
or foreign jurisdiction. 
  
 5.2 Use of Proceeds. The
Company will use the proceeds from the sale of the Shares hereunder, net of the legal and other expenses incurred by the Company in connection with this Agreement and the sale of the Shares hereunder and the other transactions contemplated hereby,
for working capital or for such other uses as may be approved by the Company’s Board of Directors. 
  
 5.3 Investment Company. The Company agrees that it shall not become an “investment company” or a company “controlled” by an
“investment company” within the meaning of the 1940 Act. In the event that the Company breaches the obligation set forth in the preceding sentence, the Company shall immediately notify Osman and take such corrective action as may be
necessary to remedy such breach. 
  
 5.4 Payment for
Waivers. The Company will not, directly or indirectly, pay or cause to be paid any remuneration or compensation, whether by way of issuing supplemental or additional capital shares, cash payments or otherwise, to any investor or other
stockholder in the Company for the purpose of inducing Osman or other stockholder to agree to waive any right arising under, or to amend any term or provision of, this Agreement or the Restated Charter, without offering to pay such remuneration or
compensation to all investors or all other stockholders ratably based on the number of capital shares then held by Osman or other stockholders which are subject to or affected by such waiver or amendment. 
  
 6. CONDITIONS OF THE
COMPANY’S OBLIGATIONS AT THE CLOSING. The obligations of the Company to Osman under this Agreement are subject to the fulfillment on or before the
Closing of each of the following conditions, the waiver of which shall not be effective unless consented to in writing by the Company: 
  
 6.1 Representations and Warranties. The representations and warranties of Osman contained in Section 3 shall be true on and as of the date of the
Closing with the same effect as though such representations and warranties had been made on and as of the date of the Closing. 
  

 16. 

 6.2 Payment of Purchase Price. Osman shall have delivered to the Company the aggregate Purchase
Price for the Shares being purchased by Osman at the Closing. 
  
 6.3 Blue Sky. The Company shall have obtained all necessary Blue Sky law permits and qualifications, or have the availability of exemptions therefrom, required by any state for the offer and sale of the Securities. 
  
 7. MISCELLANEOUS. 
  
 7.1 Survival of Warranties. The warranties, representations and
covenants of the Company and Osman contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter thereof made by
or on behalf of Osman or the Company. 
  
 7.2 Successors and
Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other
than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
  
 7.3 Governing Law. This Agreement shall be governed by and construed
under the laws of the State of Florida as applied to agreements among Florida residents entered into and to be performed entirely within Florida. 
  
 7.4 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
  
 7.5 Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
  
 7.6 Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in
writing and shall be deemed effectively given (i) upon personal delivery or delivery by nationally recognized courier service to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours
of the recipient; if not, then on the next business day, or (iii) five (5) days after having been deposited with the United States Post Office by registered or certified mail, return receipt requested, postage prepaid and addressed to the party to
be notified at the address indicated for such party on the first page of this Agreement, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties; provided, however, that
registered or certified mail shall not be used to effectuate delivery of any such notice under this Agreement if the party to be notified is located outside of the United States. 
  
 7.7 Finder’s Fee. Each party represents that it neither is, nor will be, obligated for any finders’ fee or
commission in connection with this transaction. Osman agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finder’s fee (and the costs and expenses of defending against
such liability or asserted liability) for which Osman or any of its officers, partners, employees, or representatives is 

  

 17. 

 
responsible. The Company agrees to indemnify and hold harmless Osman from any liability for any commission or compensation in the nature of a finder’s
fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 
  
 7.8 Expenses. The Company and Osman shall bear their own expenses and legal fees incurred on their behalf with
respect to this Agreement and the transactions contemplated hereby. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement (including any exhibit or schedule hereto), each party shall bear its own
attorney’s fees and related costs. 
  
 7.9 Amendments and
Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), prior to the Closing only with the
written consent of the parties hereto and after the Closing, by the Company and holders of a majority of the Shares (on an as converted basis and including any Conversion Stock into which Shares have been converted that are still owned by Osman or
their permitted transferees). Any amendment or waiver effected in accordance with this Section 7.9 shall be binding upon Osman and each holder of any securities purchased under this Agreement at the time outstanding (including securities into which
such securities are convertible), each future holder of all such securities, and the Company. 
  
 7.10 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision will be deemed amended to conform to applicable law so as to be valid, legal and
enforceable in such jurisdiction, and the validity, legality and enforceability of such provision will not be affected or impaired thereby in any other jurisdiction; if such provision cannot be amended without altering materially the intention of
the parties, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 
  
 7.11 Aggregation of Stock. All Shares held or acquired by affiliated
entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
  
 7.12 Stock Splits. All references to numbers of shares in this Agreement shall be appropriately adjusted to reflect any stock dividend, split,
combination or other recapitalization of shares by the Company occurring after the date of this Agreement. 
  
 7.13 Entire Agreement. This Agreement, and the documents referred to herein constitute the entire agreement between the parties hereto pertaining
to the subject matter hereof, and any and all other written or oral agreements existing between the parties hereto are expressly canceled. 
  
 * 
  
 * 
  

 18. 

 IN WITNESS WHEREOF, the parties have executed this
Series E Convertible Preferred Stock Purchase Agreement as of the day and year first set forth above. 
  

			
	ACCENTIA, INC.
		
	By:	 	 /s/ Francis E. O’Donnell, Jr.

	 	 	Francis E. O’Donnell, Jr.
	 	 	Chief Executive Officer

  

			
	RONALD E. OSMAN
		
	By:	 	 /s/ Ron Osman

	 	 	Ron Osman

  
 EXHIBITS

  

			
	A	  	Amended and Restated Articles of Incorporation
	B	  	Class A Warrant
	C	  	Class B Warrant
	D	  	Schedule of Exceptions
	E	  	Investors’ Rights Agreement

  
 [SIGNATURE PAGE TO SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT] 
  

  
 EXHIBIT A

  
 AMENDED AND RESTATED ARTICLES OF INCORPORATION

  

  

					
	 	  	 	  	Effective on June 18, 2003, pursuant to the Resolutions adopted by the Board of Directors dated June 18, 2003.

  
 AMENDED AND RESTATED
BY-LAWS 
 OF 
 ACCENTIA, INC. 
  
 ARTICLE I 
 OFFICES 
  
 Section 1. The principal office of the Corporation shall be located at 5310 Cypress Center Drive, Suite 101, Tampa, Florida 33609. The Corporation may
have such other offices, either within or outside of the state of Florida as the Board of Directors may designate or as the business of the Corporation may from time to time require. 
  
 ARTICLE II 
 MEETINGS OF SHAREHOLDERS 
  
 Section 1. Annual
Meeting: The annual meeting of the shareholders of the Corporation shall be held on such day as the Board of Directors shall determine. The annual meeting of the shareholders for any year shall be held no later than thirteen months after the
last preceding annual meeting of the shareholders. Business transacted at the annual meeting shall include the election of directors of the Corporation. 
  
 Section 2. Special Meetings: Special meetings of the shareholders shall be held when directed by the President, the Board of Directors, or when
requested in writing by the holders of not less than ten percent of all the shares entitled to vote at the meeting. A meeting requested by shareholders shall be called for a date not less than ten nor more than sixty days after the request is made,
unless the shareholders requesting the meeting designate a later date. The call for the meeting shall be issued by the Secretary, unless the President, Board of Directors, or shareholders requesting the meeting shall designate another person to do
so. 
  
 Section 3. Place: Meetings of shareholders may be
held within or outside of the state of Florida. If no designation is made, the place of the meeting shall be the principal office of the Corporation. 
  
 Sections 4. Notice: Written notice stating the place, day and hour of the meeting and, in the case of a special meeting, the purpose or purposes
for which the meeting is called, shall be delivered not less than ten nor more than sixty days before the meeting, either personally or by first class mail, by or at the direction of the President, the Secretary, or the officer or persons calling
the meeting to each shareholder of record entitled to vote at such meeting. If mailed, 

  

 1 

 
such notice shall be deemed to be delivered when deposited in the United States mail addressed to the shareholder at his/her address as it appears on the
stock transfer books of the Corporation, with postage thereon prepaid. 
  
 Section 5. Notice of Adjourned Meetings: When a meeting is adjourned to another place or time, it shall not be necessary to give any notice of the adjourned meeting if the place and time to which the meeting is adjourned is announced
at the meeting at which the adjournment is taken, and at the adjourned meeting any business may be transacted that might have been transacted on the original date of the meeting. If, however, after the adjournment the Board of Directors fixes a new
record date for the adjourned meeting, a Notice of the Adjourned Meeting shall be given as provided in this section to each shareholder of record on the new record date entitled to vote at such meeting. 
  
 Section 6. Closing of Transfer Books and Fixing Record Date:
For the purpose of determining shareholders entitled to notice of or to vote at any meeting of shareholders or any adjournment thereof, or entitled to receive payment of any dividend, or in order to make a determination of shareholders for any
other purpose, the Board of Directors may provide that the stock transfer books shall be closed for at least ten days immediately preceding such meeting. 
  
 In lieu of closing the stock transfer books, the Board of Directors may fix in advance a date of record for any determination of shareholders. However,
such date is not to be more than sixty days, prior and in the case of a meeting of the shareholders, such date shall not be less than ten days prior to the date on which the particular action requiring such determination of shareholders is to be
taken. 
  
 If the stock transfer books are not closed and no
record date is fixed for the determination of shareholders entitled to notice or to vote at a meeting of shareholders, or shareholders entitled to receive payment of a dividend, the date on which notice of the meeting is mailed or the date on which
the resolution of the Board of Directors declaring such dividend is adopted, as the case may be, shall be the record date for such determination of shareholders. 
  
 When a determination of shareholders entitled to vote at any meeting of shareholders has been made as provided in this
section, such determination shall apply to any adjournment thereof, unless the Board of Directors fixes a new record date for the adjourned meeting. 
  
 Section 7. Voting Record: The officers or agent having control of the stock transfer books for shares of the Corporation shall make, at least ten
days before each meeting of shareholders, a complete list of the shareholders entitled to vote at such meetings or any adjournment thereof, with the address of and the number and class and series, if any, of shares held by each. The list, for a
period of ten days prior to such meeting, shall be kept on file at the registered office of the Corporation, at the principal place of business of the Corporation or at the office of the transfer agent or registrar of the Corporation and any
shareholder shall be entitled to inspect the list at any time during usual business hours. The list shall also be produced and kept open at the time and place of the meeting and shall be subject to the inspection of any shareholder at any time
during the meeting. 
  

 - 2 - 

 If the requirements of this section have not been substantially complied with, the meeting on demand of
any shareholder in person or by proxy, shall be adjourned until the requirements are complied with. If no such demand is made, failure to comply with the requirements of this section shall not affect the validity of any action taken at such meeting.

  
 Section 8. Shareholder Quorum and Voting: A majority of
the shares entitled to vote represented in person or by proxy, shall constitute a quorum at a meeting of shareholders. When a specified item of business is required to be voted on by a class or series a majority of the shares entitled to vote shall
constitute a quorum for the transaction of such item of business by that class or series. 
  
 If a quorum is present, the affirmative vote of the majority of the shares represented at the meeting and entitled to vote on the subject matter shall be the act of the shareholders unless otherwise provided by law.

  
 After a quorum has been established at a shareholders’
meeting, the subsequent withdrawal of shareholders, so as to reduce the number of shareholders entitled to vote at the meeting below the number required for a quorum, shall not affect the validity of any action taken at a meeting or any adjournment
thereof. 
  
 Section 9. Voting of Shares: Each shareholder
entitled to vote in accordance with the terms and provisions of the Amended and Restated Articles of Incorporation of the Corporation, as amended, and these Amended and Restated By-Laws, shall be entitled to one vote for each share of stock owned by
such shareholder. Upon the demand of any shareholder, the vote for directors shall be by ballot. All other requirements as to voting, voting trusts and shareholders’ agreements shall be in accordance with the laws of the state of Florida.

  
 Section 10. Proxies: Every shareholder entitled to vote
at a meeting of shareholders or to express consent or dissent without a meeting or a shareholders’ duly authorized attorney-in-fact, may authorize another person or persons to act for him by proxy. 
  
 Every proxy must be signed by the shareholder or his attorney-in-fact. No
proxy shall be valid after the expiration of eleven months from the date thereof unless otherwise provided in the proxy. Every proxy shall be revocable at the pleasure of the shareholder executing it, except as otherwise provided by law. 

 
 The authority of the holder of a proxy to act shall not be revoked by the
incompetence or death of the shareholder who executed the proxy unless, before the authority is exercised, written notice of any adjudication of such incompetence or of such death is received by the corporate officer responsible for maintaining the
list of shareholders. 
  

 - 3 - 

 If a proxy for the same shares confers authority upon two or more persons and does not otherwise provide,
a majority of them present at the meeting, or if one is present then that one, may exercise all the powers conferred by the proxy; but if the proxy holders present at the meeting are equally divided as to the right and manner of voting in any
particular case, the voting of such shares shall be prorated. 
  
 If a proxy expressly provides, any proxy holder may appoint in writing a substitute to act in his place. 
  
 Section 11. Action by Shareholders Without a Meeting: Any action required by law, these Amended and Restated By-Laws, or the Amended and Restated
Articles of Incorporation of the Corporation, as amended, to be taken at any annual or special meeting of such shareholders, may be taken without a meeting, without prior notice and without a vote, if consent in writing, setting forth the action so
taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereof were present and voted. If
any class of shares is entitled to vote thereon as a class, such written consent shall be required of the holders of a majority of the shares of each class of shares entitled to vote as a class thereon and of the total shares entitled to vote
thereon. 
  
 Within ten days after obtaining such authorization by
written consent, notice shall be given to those shareholders who have not consented in writing. The notice shall fairly summarize the material features of the authorized action and, if the action be a merger, consolidation or sale or exchange of
assets for which dissenters rights are provided under this act, the notice shall contain a clear statement of the right of shareholders dissenting therefrom to be paid the fair value of their shares upon compliance with further provisions of this
act regarding the rights of dissenting shareholders. 
  
 ARTICLE
III 
 DIRECTORS 
  
 Section 1. Function: All corporate powers shall be exercised by or under the authority of, and the business and affairs of the Corporation shall be
managed under the direction of the Board of Directors. 
  
 Section
2. Qualification: Directors need not be residents of this state or shareholders of the Corporation. 
  
 Section 3. Compensation: The Board of Directors shall have authority to fix the compensation of directors. 
  

 - 4 - 

 Section 4. Duties of Directors: A director shall perform his duties as a director, including his
duties as a member of any committee of the board upon which he may serve, in good faith, in a manner he reasonably believes to be in the best interests of the Corporation, and with such care as an ordinarily prudent person in a like position would
use under similar circumstances. 
  
 In performing his duties, a
director shall be entitled to rely on information, opinions, reports or statements, including financial statements and other financial data, in each case prepared or presented by: 
  
 (a) one or more officers or employees of the Corporation whom the director reasonably believes to be reliable and competent
in the matters presented, 
  
 (b) counsel, public accountants or
other persons as to matters which the director reasonably believes to be within such person’s professional or expert competence, or 
  
 (c) a committee of the board upon which he does not serve, duly designated in accordance with a provision of the Amended and Restated Articles of
Incorporation of the Corporation, as amended, or these Amended and Restated By-Laws, as to matters within its designated authority, which committee the director reasonably believes to merit confidence. 
  
 A director shall not be considered to be acting in good faith if he has
knowledge concerning the matter in question that would cause such reliance described above to be unwarranted. 
  
 A person who performs his duties in compliance with this section shall have no liability by reason of being or having been a director of the Corporation.

  
 Section 5. Presumption of Assent: A director of the
Corporation who is present at a meeting of its directors at which action on any corporate matter is taken shall be presumed to have assented to the action taken unless he votes against such action or abstains from voting in respect thereto because
of an asserted conflict of interest. 
  
 Section 6. Number:
The Corporation shall be managed by a board composed of seven (7) directors, who need not be shareholders. Unless provided otherwise by the Amended and Restated Articles of Incorporation of the Corporation, as amended, the number of directors may be
increased or decreased from time to time by amendment to these Amended and Restated By-Laws, but no decrease shall have the effect of shortening the terms of an incumbent director. 
  

 - 5 - 

 Section 7. Election and Term: At the first annual meeting of shareholders and at each annual
meeting thereafter, the shareholders shall elect directors to hold office until the next succeeding annual meeting, or until a successor shall have been elected and qualified or until the earlier resignation, removal from office or death. If, at any
annual meeting of the shareholders, there are no holders of outstanding shares of the Series D Convertible Preferred Stock, then the holders of outstanding shares of the Common Stock, the Series A Convertible Preferred Stock, the Series B
Convertible Preferred Stock and the Series C Convertible Preffered Stock are entitled to vote as a single class to elect all of the directors of the Corporation. If, at any time of election of the directors of the Corporation, there is at least one
holder of outstanding shares of the Series D Convertible Preferred Stock, then the holders of outstanding shares of the Common Stock, the Series A Convertible Preferred Stock, the Series B Convertible Preferred stock and the Series C Convertible
Preffered Stock are entitled to vote as a single class to elect six (6) of the seven (7) directors of the Corporation, and the holders of outstanding shares of the Series D Convertible Preferred Stock are entitled to vote as a single class to elect
one (1) of the seven (7) directors of the Corporation (the “TEAMM Director”). 
  
 Section 8. Vacancies: Any vacancy occurring in the board of directors, including any vacancy created by reason of an increase in the number of directors, may be filled by the affirmative vote of a majority of
the remaining directors though less than a quorum. A director elected to fill a vacancy shall hold office only until the next election of directors by the shareholders. 
  
 Section 9. Removal of Directors: At a meeting of shareholders called expressly for that purpose, any director or the
entire Board of Directors may be removed, with or without cause, by a vote of the holders of a majority of the shares then entitled to vote at an election of directors. 
  
 Section 10. Quorum and Voting: A majority of the number of directors fixed by these Amended and Restated By-Laws
shall constitute a quorum of the transaction of business. The act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. Notwithstanding the foregoing sentence, all equity and
debt issuances involving the Corporation shall be approved by a majority of the directors which majority must include the TEAMM Director, unless the act is required to effectuate: (i) any sale, merger or acquisition of The Analytica Group, Inc., a
Florida corporation (“Analytica”), or (ii) any acquisitions made by Analytica. 
  
 Section 11. Executive and Other Committees: The directors, by resolution adopted by a majority of the full Board of Directors, may designate from among its members, an executive committee and other committees,
and each such committee shall serve at the pleasure of the Board with the authority contained in the Florida Statutes. The board, by resolution, may designate one or more directors as alternate members of any such committee, who may act in the place
and stead of any absent member or members at any meeting of such committee. 
  

 - 6 - 

 Section 12. Regular Meetings: A regular meeting of the directors shall be held without other
notice than this by-law, immediately after and at the same place as the annual meeting of the shareholders. 
  
 Section 13. Special Meetings: Special Meetings of the directors may be called by the President or by a majority of the directors. The person or
persons authorized to call a special meeting of the directors may fix the place for holding any special meeting of the directors called by them. Members of the Board of Directors may participate in a meeting of such board by means of a conference by
telephone or similar communications equipments by means of which all person participating in the meeting can hear each other at the same time. Participation by such means shall constitute presence in person at a meeting. 
  
 Section 14. Notice: Written notice of the time and place of Special
Meetings of directors shall be given to each director either by personal delivery or by mail, telefax, telegram or cablegram at least two days before the meeting. Notice need not be given to any director who signs a waiver of notice either before or
after the meeting. Attendance of a director at a meeting shall constitute a waiver of notice of such meeting and waiver of any and all objections to the place of the meeting, any objection to the transaction of business because the meeting is not
lawfully called or convened. The business to be transacted at or the purpose of any special meeting of the directors shall be specified in the written waiver of notice. 
  
 Section 15. Action Without a Meeting: Any action required to be taken at a meeting of the Board of Directors of the
Corporation, or any action which may be taken at a meeting of the directors or a committee thereof, may be taken without a meeting if a consent in writing, setting forth the action so to be taken, signed by a majority of the directors, or a majority
of the members of the committee, as the case may be, is filed in the minutes of the proceedings of the board or of the committee. Such consent shall have the same effect as a majority vote. 
  
 ARTICLE IV 
 OFFICERS 
  
 Section 1. Officers: The officers of the Corporation shall consist of a chief executive officer, a president, a chief financial officer, and a secretary, each of whom shall be elected by the Board of Directors. Such other officers
and assistant officers and agents as may be deemed necessary may be elected or appointed by the Board of Directors from time to time. Any two or more offices may be held by the same person. The directors shall elect officers of the Corporation
annually at the meeting of the directors held after each annual meeting of the shareholders. Each officer shall hold office until his successor shall have been duly elected and shall have qualified or until his death, resignation, or until he shall
have been removed in the manner provided herein. 
  

 - 7 - 

 Section 2. Duties of Officers: The officers of the Corporation shall have the following duties:

  
 THE CHIEF EXECUTIVE OFFICER shall be the chief executive
officer of the Corporation, shall have general and active management of the business and affairs of the Corporation, subject to the direction of the Board of Directors, shall preside at all meetings of the shareholders and Board of Directors, and
perform any other such duties as may be prescribed by the Board of Directors. The CHIEF EXECUTIVE OFFICER shall also have custody of the corporate funds and financial records, shall keep full and accurate accounts of receipts and disbursements and
render accounts thereof at the annual meetings of the shareholders and whenever else required by the Board of Directors. 
  
 THE PRESIDENT, in the absence or disability of the Chief Executive Officer, shall perform all the duties of the Chief Executive Officer, and when so
acting shall have all the powers of, and be subject to all the restrictions upon, the Chief Executive Officer. The President shall have such other powers and perform such other duties as from time to time may be prescribed by the Board of Directors
or these Bylaws. 
  
 THE CHIEF FINANCIAL OFFICER shall have
custody of the corporate funds and financial records, shall keep full and accurate accounts of receipts and disbursements and render accounts thereof at the annual meetings of the shareholders and whenever else required by the Board of Directors or
the Chief Executive Officer, and shall perform such other duties as may be prescribed by the Board of Directors or the Chief Executive Officer. 
  
 THE SECRETARY shall have custody of, and maintain, all of the corporate records except the financial records; shall record the minutes of all meetings of
the shareholders and Board of Directors, send all notices of meetings out, and perform such other duties as may be prescribed by the Board of Directors or the Chief Executive Officer. 
  
 Section 3. Removal: Any officer or agent elected or appointed by the directors may be removed with or without cause
when ever in their judgment the best interest of the Corporation would be served thereby, but such removal shall be prejudice to the contract rights, if any, of the person so removed. 
  
 ARTICLE V 
 CERTIFICATES FOR SHARES 
  
 Section 1.
Issuance: Every holder of shares in the Corporation shall be entitled to have a certificate, representing all shares to which he is entitled. No certificate shall be issued for any share until such share is fully paid. 
  

 - 8 - 

 Section 2. Form: Certificates representing shares of the Corporation shall be signed by the
President and Secretary or by such other officers authorized by the directors under the laws of the state of Florida, and may be sealed with the seal of the Corporation or a facsimile thereof. All certificates shall be consecutively numbered or
otherwise identified. All certificates representing shares shall state upon the face thereof: The name of the Corporation; that the Corporation is organized under the laws of this state; the name of the person or persons to whom issued; the number
and class or shares, if any, which such certificate represents; the par value of each share represented by such certificate or a statement that the shares are without par value. 
  
 Section 3. Lost, Stolen or Destroyed Certificates: The Corporation shall issue a new stock certificate in place of
any certificate previously issued if the holder of record of the certificate (a) makes proof in affidavit form that it has been lost, destroyed or wrongfully taken; (b) requests the issue of a new certificate before the Corporation has notice that
the certificate has been acquired by a purchaser for value in good faith and without notice of any adverse claim; (c) gives bond in such form as the Corporation may direct, to indemnify the Corporation, the transfer agent, and registrar against any
claim that may be made on account of the alleged loss, destruction, or theft of a certificate unless such bond is waived by the directors; and (d) satisfies any other reasonable requirements imposed by the Corporation. 
  
 Section 4. Transfer of Shares: Upon surrender to the Corporation or
the transfer agent of the Corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignment or authority to transfer, it shall be duty of the Corporation to issue a new certificate to the person
entitled thereto, and cancel the old certificate; every such transfer shall be entered on the transfer book of the Corporation which shall be kept at its principal office. 
  
 The Corporation shall be entitled to treat the holder of record of any share as the holder in fact thereof, and accordingly,
shall not be bound to recognize any equitable or other claim to or interest in such share on the part of any other person whether or not it shall have express or other notice thereof, except as expressly provided by the laws of this State.

  
 ARTICLE VI 
 BOOKS AND RECORDS 
  
 The Corporation shall keep correct and complete books and records of account and shall keep minutes of the proceedings of its shareholders, directors and
committees of directors upon the terms and conditions provided by law. 
  

 - 9 - 

 ARTICLE VII 
 DIVIDENDS 
  
 The directors
may from time to time declare, and the Corporation may pay, dividends on its outstanding shares upon the terms and conditions provided by law. 
  
 ARTICLE VIII 
 FISCAL YEAR

  
 The fiscal year of the Corporation shall begin on the
1st day of September in each year and end on the 31st day of August in each year. 
  
 ARTICLE IX 
 CORPORATE SEAL

  
 The directors shall provide a corporate seal which shall
be circular in form and shall have inscribed thereon the name of the Corporation, state of incorporation, year of incorporation and the words “corporate seal.” 
  
 ARTICLE X 
 AMENDMENT 
  
 These Amended and Restated By-Laws
may be repealed or amended, and new by-laws may be adopted by the Board of Directors, unless otherwise provided in the Amended and Restated Articles of Incorporation of the Corporation, as amended. 
  

 - 10 - 

  
 EXHIBIT B

  
 CLASS A WARRANT 
  

 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “1933 ACT”), OR APPLICABLE STATE SECURITIES LAWS. THIS WARRANT AND SUCH UNDERLYING SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE SOLD, MORTGAGED,
PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR THIS WARRANT AND SUCH SECURITIES UNDER THE 1933 ACT AND APPLICABLE STATE SECURITIES LAWS, OR THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION
PROVISIONS OF THE 1933 ACT AND APPLICABLE STATE SECURITIES LAWS. 
  
 ACCENTIA, INC. 
 CLASS A WARRANT 
  
 This Class A Warrant (“Warrant”) is issued as of April         ,
2004, by Accentia, Inc., a Florida corporation (the “Company”), to Ronald E. Osman or his permitted assigns (the “Holder”). 
  
 1. Issuance of Warrant; Term. 
  
 1.1 Issuance. The Company hereby grants to the Holder the right to purchase up to two million five hundred thousand (2,500,000)
shares of the Company’s Series E Convertible Preferred stock, $1.00 par value per share (the “Warrant Stock”). 
  
 1.2 Vesting and Term. This Warrant shall be exercisable to purchase the Warrant Stock at any time and from time to time from the
date hereof until April          2005 (the “Expiration Date”). The Company shall give notice to the Holder of a Public Offering at least thirty (30) days prior thereto. In the event of
a Public Offering, the Expiration Date of this Warrant shall accelerate and this Warrant shall expire on the Public Offering Date. The Public Offering Date shall mean the date on which the Company’s Common Stock is first quoted for purchase and
sales in publicly available trades. 
  
 1.3
Exercise Price. The exercise price (the “Warrant Price”) per share for which all or any of the shares of Warrant Stock may be purchased pursuant to the terms of this Warrant shall be $1.00. 
  
 2. Adjustment of Warrant Price, Number and Kind of Shares. The Warrant
Price and the number and kind of securities issuable upon the exercise of this Warrant shall be subject to adjustment from time to time and the Company agrees to provide notice upon the happening of certain events as follows. 
  
 2.1 Dividends in Stock Adjustment. In case at any
time or from time to time on or after the date hereof the Holders of Series E Convertible Preferred stock shall have received, or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to
receive, without payment therefor, other or additional securities of the Company by way 

  

 
of dividend or distribution, then and in each case, the holder of this Warrant shall, upon the exercise hereof, be entitled to receive, in addition to the
number of shares of Warrant Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of such other or additional securities of the Company which such holder would hold on the date of such exercise had it
been the holder of record of such shares of Warrant Stock on the date hereof and had thereafter, during the period from the date hereof to and including the date of such exercise, retained such shares and/or all other additional securities or other
property receivable by it as aforesaid during such period, giving effect to all adjustments called for during such period by this subsection 2.1 and subsections 2.2 and 2.3 of this Section 2. 
  
 2.2 Reclassification or Reorganization Adjustment. In
case of any reclassification, reorganization of the Company on or after the date hereof, then and in each such case the Company shall give the holder of this Warrant at least thirty (30) days notice of the proposed effective date of such
transaction, and the holder of this Warrant, upon the exercise hereof at any time after the consummation of such reclassification or reorganization, shall be entitled to receive, in lieu of the stock or other securities and property receivable upon
the exercise hereof prior to such consummation, the stock or other securities or property to which such holder would have been entitled upon such consummation if such holder had exercised this Warrant immediately prior thereto, all subject to
further adjustment as provided in subsections 2.1 and 2.3 of this Section 2. 
  
 2.3 Stock Splits and Reverse Stock Splits. If at any time on or after the date hereof the Company shall subdivide its issued and outstanding shares of Series E Convertible Preferred stock into a greater number
of shares, the Warrant Price in effect immediately prior to such subdivision shall thereby be proportionately reduced and the number of shares receivable upon exercise of this Warrant shall thereby be proportionately increased; and, conversely, if
at any time on or after the date hereof the outstanding number of shares of Series E Convertible Preferred stock shall be combined into a smaller number of shares, the Warrant Price in effect immediately prior to such combination shall thereby be
proportionately increased and the number of shares receivable upon exercise of this Warrant shall thereby be proportionately decreased. 
  
 3. No Fractional Shares. No fractional shares of Warrant Stock shall be issued in connection with any exercise hereof. In lieu of any fractional
shares that would otherwise be issuable, the Company, as determined by the Board of Directors within its sole discretion, shall: (a) pay cash equal to the product of such fraction multiplied by the fair market value of one share of Warrant Stock on
the date of exercise, as determined in good faith by the Company’s Board of Directors or (b) round up the number of shares of Warrant Stock to the next whole share. 
  
 4. No Stockholder Rights. This Warrant as such shall not entitle its holder to any of the rights of a stockholder of
the Company until the holder has exercised this Warrant. 
  
 5.
Reservation of Stock. The Company covenants that during the period that this Warrant is exercisable, the Company will reserve from its authorized and unissued capital stock a sufficient number of shares of Series E Convertible Preferred stock
to provide for the issuance of the Warrant Stock upon the exercise of this Warrant. The Company agrees that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing 

  

 2 

 
stock certificates to execute and issue the necessary certificates for shares of Warrant Stock upon the exercise of this Warrant. 
  
 6. Exercise of Warrant. This Warrant may be exercised by Holder by the
surrender of this Warrant at the principal office of the Company accompanied by payment in full of the Warrant Price of the shares of Warrant Stock purchased thereby and the completed subscription form attached hereto. This Warrant shall be deemed
to have been exercised immediately prior to the close of business on the date of its surrender for exercise as provided above, and the person or entity entitled to receive the shares of Warrant Stock issuable upon such exercise shall be treated for
all purposes as the holder of such shares of record as of the close of business on such date. As promptly as practicable, the Company shall issue and deliver to the person or entity entitled to receive the same a certificate or certificates, without
charge for any stamp or similar tax with respect to such issuance, for the number of full shares of Warrant Stock issuable upon such exercise, together with cash in lieu of any fraction of a share as provided above. The shares of Warrant Stock
issuable upon exercise hereof shall, upon their issuance, be fully paid and nonassessable. 
  
 7. Certificate of Adjustment. Whenever the Warrant Price or number or type of securities issuable upon exercise of this Warrant is adjusted, as herein provided, the Company shall promptly deliver to the record
holder of this Warrant a certificate of an officer of the Company setting forth the nature of such adjustment and a brief statement of the facts requiring such adjustment. 
  
 8. Notice of Proposed Transfers. Prior to any proposed transfer of this Warrant or the shares of Warrant Stock
received on the exercise of this Warrant (the “Securities”), unless there is in effect a registration statement under the Securities Act of 1933, as amended and applicable state securities laws (collectively, the “Securities
Laws”), covering the proposed transfer, the Holder thereof shall give written notice to the Company of such Holder’s intention to effect such transfer. Each such notice shall describe the manner and circumstances of the proposed
transfer in sufficient detail, and shall, if the Company so reasonably requests, be accompanied (except in transactions in compliance with Rule 144) by a written opinion of legal counsel to the effect that the proposed transfer of the Securities may
be effected without registration under the Securities Laws, whereupon the Holder of the Securities shall be entitled to transfer the Securities in accordance with the terms of the notice delivered by the Holder to the Company. Each certificate
evidencing the Securities transferred as above provided shall bear the appropriate restrictive legend set forth above, except that such certificate shall not bear such restrictive legend if in the opinion of counsel for the Company such legend is
not required in order to establish compliance with any provisions of the Securities Laws. 
  
 9. Replacement of Warrants. Upon the receipt by the Company of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and in the case of any such loss, theft or
destruction of the Warrant indemnification or bond where reasonably required or upon surrender and cancellation of this Warrant if mutilated, the Company will execute and deliver, in lieu thereof, a new Warrant of like tenor. 
  
 10. Miscellaneous. This Warrant shall be enforced, governed and
construed in all respects in accordance with the laws of the State of Florida, without application of the principles of 

  

 3 

 
conflicts of laws in a manner that would cause Florida law not to be applied to the substance of any controversy. The headings in this Warrant are for
purposes of convenience of reference only, and shall not be deemed to constitute a part hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provisions. All notices and
other communications from the Company to the holder of this Warrant shall be delivered personally or mailed by first class mail, postage prepaid, to the address furnished to the Company in writing by the last holder of this Warrant who shall have
furnished an address to the Company in writing, and if mailed shall be deemed given three days after deposit in the U.S. Mail. 
  
 11. Taxes. The Company shall pay all issue taxes and other governmental charges (but not including any income taxes of a Holder) that may be
imposed in respect of the issuance or delivery of the Shares or any portion thereof. 
  
 12. Amendment. Any term of this Warrant may be amended with the written consent of the Company and the Holder of this Warrant. Any amendment effected in accordance with this Section 12 shall be binding upon the
Holder of this Warrant, each future holder of such Warrant, and the Company. 
  
 IN WITNESS WHEREOF, the undersigned officer of the Company has set his hand as of the date first above written. 
  

			
	ACCENTIA, INC
		
	By:	 	__________________ Its:__________________

  

 4 

  
 Subscription

  

									
					
	To:	 	 	 	 	 	 Date:
	 	 

  
 The undersigned hereby
exercises this Series A Warrant and subscribes for              shares of Warrant Stock covered by this Warrant. The certificate(s) for such shares shall be issued in the name of the
undersigned or as otherwise indicated below: 
  

	
	
	 
	Signature
	
	 
	Name for Registration
	
	 
	Mailing Address

  

  
 EXHIBIT C

  
 CLASS B WARRANT 
  

 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE “1933 ACT”), OR APPLICABLE STATE SECURITIES LAWS. THIS WARRANT AND SUCH UNDERLYING SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE SOLD, MORTGAGED,
PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT FOR THIS WARRANT AND SUCH SECURITIES UNDER THE 1933 ACT AND APPLICABLE STATE SECURITIES LAWS, OR THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION
PROVISIONS OF THE 1933 ACT AND APPLICABLE STATE SECURITIES LAWS. 
  
 ACCENTIA, INC. 
 CLASS B WARRANT 
  
 This Class B Warrant (“Warrant”) is issued as of April         ,
2004, by Accentia, Inc., a Florida corporation (the “Company”), to Ronald E. Osman or his permitted assigns (the “Holder”). 
  
 1. Issuance of Warrant; Term. 
  
 1.1 Issuance. The Company hereby grants to the Holder the right to purchase up to two million five hundred thousand (2,500,000)
shares of the Company’s Series E Convertible Preferred stock, $1.00 par value per share (the “Warrant Stock”). 
  
 1.2 Vesting and Term. This Warrant shall be exercisable to purchase the Warrant Stock at any time and from time to time from the
date hereof until April        2006 (the “Expiration Date”). Before the exercise of this Series B Warrant and as a condition to the exercise of this Series B Warrant, the Series A
Warrant issued on even date herewith must be exercised in full. The Company shall give notice to the Holder of a Public Offering at least thirty (30) days prior thereto. In the event of a Public Offering, the Expiration Date of this Warrant shall
accelerate and this Warrant shall expire on the Public Offering Date. The Public Offering Date shall mean the date on which the Company’s Common Stock is first quoted for purchase and sales in publicly available trades. 
  
 1.3. Exercise Price. The exercise price (the
“Warrant Price”) per share for which all or any of the shares of Warrant Stock may be purchased pursuant to the terms of this Warrant shall be $1.00. 
  
 2. Adjustment of Warrant Price, Number and Kind of Shares. The Warrant Price and the number and kind of securities
issuable upon the exercise of this Warrant shall be subject to adjustment from time to time and the Company agrees to provide notice upon the happening of certain events as follows. 
  
 2.1 Dividends in Stock Adjustment. In case at any time or from time to time on or after the date
hereof the Holders of Series E Convertible Preferred stock shall have received, or, 

  

 
on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without payment therefor, other or
additional securities of the Company by way of dividend or distribution, then and in each case, the holder of this Warrant shall, upon the exercise hereof, be entitled to receive, in addition to the number of shares of Warrant Stock receivable
thereupon, and without payment of any additional consideration therefor, the amount of such other or additional securities of the Company which such holder would hold on the date of such exercise had it been the holder of record of such shares of
Warrant Stock on the date hereof and had thereafter, during the period from the date hereof to and including the date of such exercise, retained such shares and/or all other additional securities or other property receivable by it as aforesaid
during such period, giving effect to all adjustments called for during such period by this subsection 2.1 and subsections 2.2 and 2.3 of this Section 2. 
  
 2.2 Reclassification or Reorganization Adjustment. In case of any reclassification, reorganization of the Company on or after the
date hereof, then and in each such case the Company shall give the holder of this Warrant at least thirty (30) days notice of the proposed effective date of such transaction, and the holder of this Warrant, upon the exercise hereof at any time after
the consummation of such reclassification or reorganization, shall be entitled to receive, in lieu of the stock or other securities and property receivable upon the exercise hereof prior to such consummation, the stock or other securities or
property to which such holder would have been entitled upon such consummation if such holder had exercised this Warrant immediately prior thereto, all subject to further adjustment as provided in subsections 2.1 and 2.3 of this Section 2.

  
 2.3 Stock Splits and Reverse Stock
Splits. If at any time on or after the date hereof the Company shall subdivide its issued and outstanding shares of Series E Convertible Preferred stock into a greater number of shares, the Warrant Price in effect immediately prior to such
subdivision shall thereby be proportionately reduced and the number of shares receivable upon exercise of this Warrant shall thereby be proportionately increased; and, conversely, if at any time on or after the date hereof the outstanding number of
shares of Series E Convertible Preferred stock shall be combined into a smaller number of shares, the Warrant Price in effect immediately prior to such combination shall thereby be proportionately increased and the number of shares receivable upon
exercise of this Warrant shall thereby be proportionately decreased. 
  
 3. No Fractional Shares. No fractional shares of Warrant Stock shall be issued in connection with any exercise hereof. In lieu of any fractional shares that would otherwise be issuable, the Company, as determined by the Board of
Directors within its sole discretion, shall: (a) pay cash equal to the product of such fraction multiplied by the fair market value of one share of Warrant Stock on the date of exercise, as determined in good faith by the Company’s Board of
Directors or (b) round up the number of shares of Warrant Stock to the next whole share. 
  
 4. No Stockholder Rights. This Warrant as such shall not entitle its holder to any of the rights of a stockholder of the Company until the holder has exercised this Warrant. 
  
 5. Reservation of Stock. The Company covenants that during the period
that this Warrant is exercisable, the Company will reserve from its authorized and unissued capital stock a sufficient number of shares of Series E Convertible Preferred stock to provide for the issuance of the Warrant Stock upon the exercise of
this Warrant. The Company agrees that its issuance of this 

  

 2 

 
Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary
certificates for shares of Warrant Stock upon the exercise of this Warrant. 
  
 6. Exercise of Warrant. This Warrant may be exercised by Holder by the surrender of this Warrant at the principal office of the Company accompanied by payment in full of the Warrant Price of the shares of
Warrant Stock purchased thereby and the completed subscription form attached hereto. This Warrant shall be deemed to have been exercised immediately prior to the close of business on the date of its surrender for exercise as provided above, and the
person or entity entitled to receive the shares of Warrant Stock issuable upon such exercise shall be treated for all purposes as the holder of such shares of record as of the close of business on such date. As promptly as practicable, the Company
shall issue and deliver to the person or entity entitled to receive the same a certificate or certificates, without charge for any stamp or similar tax with respect to such issuance, for the number of full shares of Warrant Stock issuable upon such
exercise, together with cash in lieu of any fraction of a share as provided above. The shares of Warrant Stock issuable upon exercise hereof shall, upon their issuance, be fully paid and nonassessable. 
  
 7. Certificate of Adjustment. Whenever the Warrant Price or number or
type of securities issuable upon exercise of this Warrant is adjusted, as herein provided, the Company shall promptly deliver to the record holder of this Warrant a certificate of an officer of the Company setting forth the nature of such adjustment
and a brief statement of the facts requiring such adjustment. 
  
 8. Notice of Proposed Transfers. Prior to any proposed transfer of this Warrant or the shares of Warrant Stock received on the exercise of this Warrant (the “Securities”), unless there is in effect a registration
statement under the Securities Act of 1933, as amended and applicable state securities laws (collectively, the “Securities Laws”), covering the proposed transfer, the Holder thereof shall give written notice to the Company of such
Holder’s intention to effect such transfer. Each such notice shall describe the manner and circumstances of the proposed transfer in sufficient detail, and shall, if the Company so reasonably requests, be accompanied (except in transactions in
compliance with Rule 144) by a written opinion of legal counsel to the effect that the proposed transfer of the Securities may be effected without registration under the Securities Laws, whereupon the Holder of the Securities shall be entitled to
transfer the Securities in accordance with the terms of the notice delivered by the Holder to the Company. Each certificate evidencing the Securities transferred as above provided shall bear the appropriate restrictive legend set forth above, except
that such certificate shall not bear such restrictive legend if in the opinion of counsel for the Company such legend is not required in order to establish compliance with any provisions of the Securities Laws. 
  
 9. Replacement of Warrants. Upon the receipt by the Company of
evidence satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and in the case of any such loss, theft or destruction of the Warrant indemnification or bond where reasonably required or upon surrender and
cancellation of this Warrant if mutilated, the Company will execute and deliver, in lieu thereof, a new Warrant of like tenor. 
  

 3 

 10. Miscellaneous. This Warrant shall be enforced, governed and construed in all respects in
accordance with the laws of the State of Florida, without application of the principles of conflicts of laws in a manner that would cause Florida law not to be applied to the substance of any controversy. The headings in this Warrant are for
purposes of convenience of reference only, and shall not be deemed to constitute a part hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provisions. All notices and
other communications from the Company to the holder of this Warrant shall be delivered personally or mailed by first class mail, postage prepaid, to the address furnished to the Company in writing by the last holder of this Warrant who shall have
furnished an address to the Company in writing, and if mailed shall be deemed given three days after deposit in the U.S. Mail. 
  
 11. Taxes. The Company shall pay all issue taxes and other governmental charges (but not including any income taxes of a Holder) that may be
imposed in respect of the issuance or delivery of the Shares or any portion thereof. 
  
 12. Amendment. Any term of this Warrant may be amended with the written consent of the Company and the Holder of this Warrant. Any amendment effected in accordance with this Section 12 shall be binding upon the
Holder of this Warrant, each future holder of such Warrant, and the Company. 
  
 IN WITNESS WHEREOF, the undersigned officer of the Company has set his hand as of the date first above written. 
  
 ACCENTIA, INC 
  
 By:                                     
   
Its:                                       
      
  

 4 

 Subscription 
  

							
	 To:
	 	 	 	Date:	 	 

  
 The undersigned hereby
exercises this Series B Warrant and subscribes for              shares of Warrant Stock covered by this Warrant. The certificate(s) for such shares shall be issued in the name of the
undersigned or as otherwise indicated below: 
  

	
	
	 
	Signature
	
	 
	Name for Registration
	
	 
	Mailing Address

  

  
 EXHIBIT D

  
 SCHEDULE OF EXCEPTIONS 
  

  
 EXHIBIT D 

 
 SCHEDULE OF EXCEPTIONS 
  
 1. Section 2.10, Section 2.12 and Section 2.15. Other than security agreements, and rights
and interests there under, granted to Harbinger Mezzanine Partners, L.P. by Teamm Pharmaceuticals, Inc. and by Accent Rx, Inc. and Accentia, Inc. to McKesson Corporation. 
  
 2. Section 2.26. Schedule 2.26—“List of Shareholders” is attached. 
  
 2. Section 2.27. Schedule 2.27. Accounts payable and contractual obligations which arose in
the ordinary course of business since September 30, 2003; unperformed obligations under contracts and commitments; $75,000 payable in 2005 arising our of the asset purchase in the IMOR-Analytica GmbH transaction; and unasserted contingent
obligations and liabilities from the conduct of our business or outstanding contracts. 
  

  
 EXHIBIT E

  
 INVESTORS’ RIGHTS AGREEMENT 
  

  
 ACCENTIA, INC.

  
 INVESTORS’ RIGHTS AGREEMENT 

 
 THIS INVESTORS’
RIGHTS AGREEMENT (this “Agreement”) is made as of April     , 2004 by and among ACCENTIA, INC., a Florida
corporation, having its principal place of business located at 5310 Cypress Center Drive, Suite 101, Tampa, FL 33609 (the “Company”), and Ronald E. Osman, 6530 Moake School Rd, Marion, Il, 62959
(“Osman”). 
  
 RECITALS

  
 WHEREAS, Osman is a party to the
Series E Convertible Preferred Stock Purchase Agreement of even date herewith by and among the Company and Osman (the “Series E Stock Purchase Agreement”), which provides that as a condition to the closing of the sale of
2,500,000 shares of the Company’s Series E Convertible Preferred Stock (the “Series E Stock”), this Agreement must be executed and delivered by the Company. 
  
 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein,
the parties hereto further agree as follows: 
  
 AGREEMENT

  
 1. REGISTRATION
RIGHTS. The Company covenants and agrees as follows: 
  
 1.1 Definitions. For purposes of this Section 1: 
  
 (a) The term “register,” “registered,” and
“registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act of 1933, as amended (the “Act”), and the declaration
or ordering of effectiveness of such registration statement or document; 
  
 (b) The term “Registrable Securities” means the (i) Common Stock issuable or issued upon conversion of the Series E Stock issued or issuable in connection with the Series E Stock
Purchase Agreement, whether such Series E Stock is issued at the Closing or subsequent thereto upon the exercise of any warrants issued to Osman pursuant to the Series E Stock Purchase Agreement ; and (ii) any Common Stock of the Company issued as
(or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, any Series E Stock; 
  
 (c) The number of shares of “Registrable
Securities then outstanding” shall be determined by the number of shares of Common Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are,
Registrable Securities; 
  
 (d) The term
“Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.12 hereof, including Osman; and 
  

 1. 

 (e) The term “Form S-3” means such form under the Act as
in effect on the date hereof or any registration form under the Act subsequently adopted by the Securities and Exchange Commission (the “SEC”) which permits inclusion or incorporation of substantial information by reference
to other documents filed by the Company with the SEC. 
  
 (f) The term “Qualifying IPO” means the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Act, as amended, covering the offer and sale of
Common Stock for the account of the Company to the public (an “Initial Public Offering”) in which the public offering price exceeds (prior to underwriter’s discounts or commissions and offering expenses) a price per
share (adjusted for any subsequent stock splits, stock dividends, reclassifications or recapitalizations) that implies a minimum aggregate enterprise value for the Company, on a fully diluted share basis, of not less than $200,000,000 and the
aggregate gross proceeds raised by the Company (after all underwriting discounts) shall equal or exceed $30,000,000. 
  
 1.2 Request for Registration. 
  
 (a) If the Company shall receive at any time after the earlier of (i) eighteen (18) months after the date hereof or (ii) six (6)
months following the effective date of the first registration statement for a public offering of securities of the Company (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock
option, stock purchase or similar plan or a SEC Rule 145 transaction) (the “Initial Registration”), a written request from the Holders of at least twenty percent (20%) of the Registrable Securities (the “Initiating
Holders”) that the Company file a registration statement under the Act covering the registration of such Holders’ Registrable Securities with an aggregate offering price expected to exceed $2,000,000, then the Company shall, within
ten (10) days of the receipt thereof, give written notice of such request to all Holders and shall, subject to the limitations of Section 1.2(b), use its best efforts to effect as soon as practicable the registration under the Act of all Registrable
Securities which the Holders request to be registered within twenty (20) days of the mailing of such written notice by the Company; provided, however, that the Company shall not be obligated to take any action to effect any such
registration, qualification or compliance pursuant to this Section 1.2(a): 
  
 (i) During the period starting with the date ninety (90) days prior to the Company’s estimated date of filing of, and ending on the date one hundred eighty (180) days immediately following the effective
date of, any registration statement pertaining to securities of the Company (other than a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan), provided that the Company is actively employing in good
faith all reasonable efforts to cause such registration statement to become effective; 
  
 (ii) After the Company has effected two (2) such registrations pursuant to this Section 1.2(a), and such registrations have been
declared or ordered effective; 
  
 (iii)
If the Company shall furnish to such Holders a certificate signed by the Chief Executive Officer or President of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or
its stockholders for a registration statement to be filed at such time, then the Company’s obligation 

  

 2. 

 
to use its best efforts to register, qualify or comply under this Section 1.2(a) shall be deferred for a period not to exceed 60 days (which may be extended
by the Company for an additional 60 days if in the good faith judgment of the Board of Directors the serious detriment was continuing) from the date of receipt of written request from the Holders; provided, however, that the Company
may not utilize this right more than once in any twelve-month period. 
  
 (b) If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to
this Section 1.2, and the Company shall include such information in the written notice referred to in Section 1.2(a). In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such
Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 1.4(e)) enter into an underwriting agreement in customary form with the
underwriter or underwriters selected for such underwriting by a majority in interest of the Initiating Holders. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing
factors require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable
Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each Holder
participating in such underwriting. 
  
 1.3
Company Registration. If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its stock or other
securities under the Act in connection with the public offering of such securities solely for cash (other than a registration relating solely to the sale of securities to participants in a Company stock plan, or a registration on any form which does
not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities), the Company shall, at such time, promptly give each Holder written notice of such
registration. Upon the written request of each Holder given within twenty (20) days after mailing of written notice by the Company, the Company shall, subject to the provisions of Section 1.8, cause to be registered under the Act all of
the Registrable Securities that each such Holder has requested to be registered. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 1.3 prior to the effectiveness of such registration
whether or not any Holder has elected to include securities in such registration. The registration expenses of such withdrawn registration shall be borne by the Company in accordance with Section 1.7 hereof. 
  

 3. 

 1.4 Obligations of the Company. Whenever required under this Section 1 to effect
the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
  
 (a) Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its best efforts to
cause such registration statement to become effective, and keep such registration statement effective for the earlier of ninety (90) days from the effective date of the Registration Statement or until the distribution described in the Registration
Statement has been completed. 
  
 (b)
Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the
disposition of all securities covered by such registration statement. 
  
 (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in
order to facilitate the disposition of Registrable Securities owned by them. 
  
 (d) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the
Holders, provided, however, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions.

  
 (e) In the event of any underwritten
public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform
its obligations under such an agreement. 
  
 (f) Notify each Holder covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances
then existing. 
  
 (g) Furnish, at the
request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1,
if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, an opinion, dated such date, of
the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting
registration of Registrable Securities. 
  
 1.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall
furnish to the Company, 

  

 4. 

 
promptly upon request, such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as
shall be required to effect the registration of such Holder’s Registrable Securities. 
  
 1.6 Expenses of Registrations. The Company shall bear and pay all expenses incurred in connection with any registration,
filing or qualification of Registrable Securities with respect to the registrations pursuant to Sections 1.2, 1.3 and 1.11 for each Holder (which right may be assigned as provided in Section 1.12), including (without limitation) all registration,
filing, and qualification fees, printers and accounting fees relating or apportionable thereto, but excluding stock transfer taxes, and any underwriting discounts and commissions and any legal fees incurred by Holder relating to Registrable
Securities. 
  
 1.7 Underwriting
Requirements. In connection with any offering involving an underwriting of shares being issued by the Company, the Company shall not be required under Section 1.3 to include any of the Holders’ securities in such underwriting unless they
accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as will not, in the opinion of the underwriters,
jeopardize the success of the offering by the Company, but in no event will the amount of Registrable Securities of the selling Holders included in the offering be reduced below twenty percent (20%) of the total amount of securities included in such
offering, unless such offering is the initial public offering of the Company’s securities in which case the selling stockholders may be excluded entirely if the underwriters make the determination described above and no other stockholder’s
securities are included. If the underwriter determines in good faith that marketing factors require a limitation in the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated (i) first,
to the Company; (ii) second to the Holders on a pro rata basis based on the number of Registrable Securities held by the Holders; and (iii) third to any other stockholder of the Company (other than a Holder) on a pro rata basis; provided,
however, that in no event shall any Holder be restricted from including such Holder’s Registrable Securities in an offering pursuant to this Section 1.7 unless and until all other holders of securities of the Company have been entirely
restricted. For purposes of apportionment, any selling stockholder which is a Holder of Registrable Securities and which is a partnership or corporation, the partners, retired partners and stockholders of such Holder, or the estates and family
members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling stockholder,” and any pro rata reduction with respect to such “selling
stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “selling stockholder,” as defined in this sentence. 
  
 1.8 Delay of Registration. No Holder
shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 
  

 5. 

 1.9 Indemnification. In the event any Registrable Securities are included
in a registration statement under this Section 1: 
  
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any underwriter (as defined in the Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning
of the Act or the Securities Exchange Act of 1934, amended (the “1934 Act”), against any losses, claims, damages, or liabilities (joint or several) to which such Holder, underwriter or controlling person may become subject
under the Act, the 1934 Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations of the Company
(collectively a “Violation”): (i) any untrue statement or alleged untrue statement of the Company of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto, (ii) the omission or alleged omission by the Company to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation
or alleged violation by the Company of the Act, the 1934 Act, any state securities law or any rule or regulation promulgated under the Act, the 1934 Act or any state securities law; and the Company will pay to each such Holder, underwriter or
controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement
contained in this Section 1.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably
withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by any such Holder, underwriter or controlling person. 
  
 (b) To the extent permitted by law, each selling Holder will severally, not jointly, indemnify and hold harmless the Company, each
of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other Holder selling securities in such registration statement and
any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, the 1934 Act or other federal or state
law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in
conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified
pursuant to this Section 1.9(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 1.9(b) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided, that, in no event shall any indemnity under
this Section 1.9(b) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. 
  

 6. 

 (c) Promptly after receipt by an indemnified party under this Section 1.9 of
notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.9, deliver to the indemnifying party a written
notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof
with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure
to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party
under this Section 1.9, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.9. 
  
 (d) If the indemnification provided for in this
Section 1.9 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such
indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations;
provided, that, in no event shall any indemnity under this Section 1.9(d) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the
indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
  
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
  
 (f) The obligations of the Company and Holders under
this Section 1.9 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 
  
 1.10 Reports Under Securities Exchange Act of 1934. With a view to making available to the Holders the benefits of Rule 144
promulgated under the Act (“Rule 144”) and any other rule or regulation of the SEC that may at any time permit a Holder 

  

 7. 

 
to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to: 
  
 (a) make and keep public information available, as
those terms are understood and defined in Rule 144, at all times after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public; 
  
 (b) take such action, including the voluntary
registration of its Common Stock under Section 12 of the 1934 Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal
year in which the first registration statement filed by the Company for the offering of its securities to the general public is declared effective; 
  
 (c) file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act;
and 
  
 (d) furnish to any Holder, so long
as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first
registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time
after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of
any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 
  
 1.11 Form S-3 Registration. In case the Company shall receive from any Holder or Holders who hold in excess of thirty
percent (30%) of the Registrable Securities, a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such
Holder or Holders, the Company will: 
  
 (a)
promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and 
  
 (b) as soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as
would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other
Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect
any such registration, qualification or compliance, pursuant to this Section 1.11: (i) if Form S-3 is not available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of 

  

 8. 

 
less than $500,000; (iii) if the Company shall furnish to the Holders a certificate signed by the Chief Executive Officer or President of the Company stating
that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 Registration to be effected at such time, in which event the Company shall have the
right to defer the filing of the Form S-3 registration statement for a period of not more than 60 days (which may be extended by the Company for an additional 60 days if in the good faith judgment of the Board of Directors the serious detriment was
continuing) after receipt of the request of the Holder or Holders under this Section 1.11; provided, however, that the Company shall not utilize this right more than once in any twelve (12) month period; or (iv) in any particular
jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 
  
 (c) If the Holders initiating the registration
request hereunder (the “Participating Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as part of their request made pursuant to
this Section 1.11 and the Company shall include such information in the written notice referred to in Section 1.11(a). In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Participating Holders and
such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 1.4(e)) enter into an underwriting agreement in customary form with
the underwriter or underwriters selected for such underwriting by a majority in interest of the Participating Holders. Notwithstanding any other provision of this Section 1.11, if the underwriter advises the Participating Holders in writing that
marketing factors require a limitation of the number of shares to be underwritten, then the Participating Holders shall so advise all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares
of Registrable Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Participating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company
owned by each Holder. 
  
 (d) Subject to
the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. Registrations
effected pursuant to this Section 1.11 shall not be counted as the demand for registration or registrations effected pursuant to Sections 1.2 or 1.3, respectively. 
  
 1.12 Assignment of Registration Rights. The rights to cause the Company to register
Registrable Securities pursuant to this Section 1 may be assigned by a Holder to any of the following transferees or assignees of Registrable Securities: (i) any such transferee or assignee who holds, subsequent to such transfer, five percent (5%)
of the total number of shares of Registrable Securities (as adjusted for stock splits, bonuses, combinations, and the like); or (ii) a subsidiary, wholly-owned entity, parent, affiliate, member, stockholder, officer, general partner, limited partner
or former or retired partner or member of a Holder; or (iii) a Holder’s family member or trust for the benefit of an individual Holder or any family member; 

  

 9. 

 
provided, however, that (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address
of such transferee or assignee and the securities with respect to which such registration rights are being assigned and (b) such assignment shall be effective only if immediately following such transfer the transferee is bound by the terms and
conditions of this Agreement and such transfer of any Registrable Securities is lawful under all applicable securities laws. 
  
 1.13 Termination of Registration Rights. No stockholder shall be entitled to exercise any right provided for in this Section 1
(except rights pursuant to Section 1.10) after the earlier of (i) three (3) years following the consummation of the sale of securities pursuant to an Initial Public Offering, or (ii) as to a given Holder, when such Holder can sell all of such
Holder’s Registrable Securities in a consecutive ninety (90) day period pursuant to Rule 144. 
  
 1.14 Limitations on Subsequent Registration Rights. Except with respect to substantially identical registration rights that may be
granted to other holders of Series E Stock and Series F Convertible Preferred Stock (“Series F Stock”), if created, with respect to such Series E Stock or Series F Stock (and the Common Stock obtained upon conversion) held by
them, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities, enter into any agreement (other than this Agreement) with any holder or prospective holder of any securities of the Company
which would allow such holder or prospective holder (i) to include securities of the Company in any Registration Statement upon terms which are the same or more favorable to such holder or prospective holder than the terms on which holders of
Registrable Securities may include shares in such registration or (ii) to make a demand registration which could result in such registration statement being declared effective prior to the dates set forth in Section 1.2. 
  
 2. INFORMATION RIGHTS.

  
 2.1 Inspection. The Company
shall permit each Holder holding, together with its affiliates (which may include, without limitation, any person or entity to which rights can be transferred pursuant to Section 3.4, below), an aggregate of at least 1,000,000 shares of the Series E
Stock (each, a “Major Holder” and collectively, the “Major Holders”), at such Major Holder’s expense to visit and inspect the Company’s properties, to examine its books of account and records
and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Major Holder; provided, however, that the Company shall not be obligated pursuant to this
Section 2.1 to provide access to any information which it reasonably considers to be a trade secret or similar confidential information unless such Major Holder agrees in writing to hold such information in confidence. 
  
 2.2 Delivery of Financial Statements.

  
 (a) The Company shall deliver to each
Holder of Series E Stock: 
  
 (1) as soon
as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company commencing with the fiscal year ended December 31, 2003, a balance sheet dated as of the last day of such fiscal 

  

 10. 

 
year, and statements of operations, cash flow and stockholders’ equity for such fiscal year. Such year-end financial reports to be in reasonable detail,
prepared in accordance with generally accepted accounting principles (“GAAP”), and audited and certified by independent public accountants of nationally recognized standing selected by the Company; 
  
 (2) within forty five (45) days of the end of each
fiscal quarter of the Company commencing with the fiscal quarter ended December 31, 2003, an unaudited statement of operations and balance sheet for and as of the end of such quarter, in reasonable detail and prepared in accordance with GAAP,
subject to year end audit adjustments and the absence of footnotes; and 
  
 (b) The Company shall deliver to each Major Holder: 
  
 (1) as soon as practicable, but in any event within thirty (30) days prior to the end of the Company’s fiscal year, an annual
budget and operating plan for the Company for the following fiscal year; 
  
 (2) as soon as practicable after the end of each month, and in any event within thirty (30) days thereafter, an unaudited statement of operations and balance sheet for such month, in reasonable detail and
prepared in accordance with GAAP, subject to year end audit adjustments and the absence of footnotes. 
  
 2.3 Termination of Information Rights. The covenants set forth in this Section 2 shall terminate as to all Holders and Major
Holders and be of no further force and effect (i) upon the consummation of a Qualifying IPO or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Securities Exchange Act of 1934,
whichever event shall first occur. 
  
 3.
INVESTORS’ RIGHT OF FIRST REFUSAL. 
  
 3.1 Right of First Refusal. The Company hereby grants to each Holder, on the terms set forth in this Section 3, the right of
first refusal to purchase all or any part of such Holder’s pro rata share of the New Securities (as defined in Section 3.2) which the Company may, from time to time, propose to sell and issue (the “Right of First
Refusal”). The Holders may purchase said New Securities on the same terms and at the same price at which the Company proposes to sell the New Securities. For the purposes of this right of first refusal, a Holder’s pro rata share of
the New Securities is a fraction, the numerator of which is the total number of shares of Common Stock held by such Holder (including any shares of Common Stock issuable upon conversion of the Series E Stock held by or issuable to such Holder) and
the denominator of which is the total number of shares of the Company’s Common Stock outstanding (including any shares of Common Stock issuable upon conversion of or exercise of, as the case may be, Preferred Stock) immediately prior to the
issuance of the New Securities; provided, however, if it is impossible or impractical, as determined in the sole discretion of Holder’s of a majority of the Series E Stock, to determine the applicable pro rata percentage in accordance with the
preceding sentences of this Section 3.1, then such majority may elect for the applicable pro rata percentage to be set at 15%. 
  

 11. 

 3.2 New Securities. “New
Securities” shall mean any capital stock of the Company, whether now authorized or not, and any rights, options or warrants to purchase said capital stock, and securities of any type whatsoever that are, or
may become, convertible into said capital stock; provided, however, that New Securities shall not include (i) the Series E Stock, (ii) shares of Common Stock issuable upon conversion of Preferred Stock, (iii) securities offered
pursuant to a registration statement filed under the Act, (iv) securities issued pursuant to the acquisition of another corporation by the Company by merger, purchase of substantially all of the assets or other reorganization, or in any transaction
in which the Company’s stockholders immediately prior to such transaction own immediately after such transaction not less than 51% of the voting power of the surviving corporation or its parent, (v) up to 10,000,000 shares of capital stock
and/or stock options issued to officers, employees, consultants or advisors pursuant to the Company’s stock option plans; (vi) securities issued in connection with leases or bank financing arrangements or corporate partnering, licensing or
similar transactions, provided that such transactions and the issuance of shares therein has been approved by the Board of Directors of the Company, (vii) any warrants, options or rights (and any shares of Common Stock or Preferred Stock issued or
issuable upon the exercise of such warrants, options or rights) to purchase shares of Common Stock or Preferred Stock that are outstanding as of the date of this Agreement, and (viii) securities issued in connection with any stock split, stock
dividend or distribution, or recapitalization by the Company approved by the Company’s Board of Directors. 
  
 3.3 Notice of Proposed Issuance. In the event the Company proposes to undertake an issuance of New Securities, it shall give
to the Holders written notice (the “Notice”) of its intention, describing the type of New Securities, the price, the terms upon which the Company proposes to issue the same, the date of the proposed issuance and a statement
as to the number of days from receipt of such Notice within which the Holders must respond to such Notice. The Holders shall have twenty (20) days from the date of receipt of the Notice to purchase any or all of the New Securities for the price and
upon the terms specified in the Notice by giving written notice to the Company and stating therein the quantity of New Securities to be purchased and forwarding payment for such New Securities to the Company if immediate payment is required by such
terms, or in any event no later than the date of the proposed issuance as set forth in the Notice. If not all of the Holders elect to purchase their pro rata share of the New Securities, then the Company shall promptly notify in writing the Holders
who do so elect to purchase all of their pro rata portion of the New Securities and shall offer such subscribing Holders the right to acquire their pro rata portion of any unsubscribed New Securities. Each subscribing Holder shall have five (5) days
after receipt of such notice to notify the Company in writing of its election to purchase all of its pro rata portion of the unsubscribed New Securities. If the Holders fail to exercise in full their first refusal rights, the Company may sell the
New Securities for which the Holders first refusal rights were not exercised, at a price and upon terms and conditions no more favorable then specified in the Notice. 
  
 3.4 Transfer of Rights. The right of first refusal granted under this Section 3 may not be
assigned or transferred, except that such right is assignable or transferable by each Holder to any transferee or assignee (i) who is a partner or member (or retired partner or member) of a Holder or the estate of such partner or member (or retired
partner or member) or (ii) that is a wholly owned subsidiary or parent of, or to any corporation 

  

 12. 

 
or entity that is, within the meaning of the Act, controlling, controlled by or under common control with, any such Holder; provided, however,
that the provisions of this Section 3 shall be binding upon any such assignee or transferee. 
  
 3.5 Termination of Rights. The right of first refusal granted under this Section 3 shall expire upon the first to occur of
(i) consummation of a Qualifying IPO, (ii) the sale, assignment or other transfer of the Registrable Securities or the Series E Stock, or (iii) the conversion of the Series E Stock into Common Stock. 
  
 4. MISCELLANEOUS PROVISIONS. 

 
 4.1 Waivers and Amendments. Any term of
this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Holders of at
least a majority of the Registrable Securities. Any amendment or waiver effected in accordance with this Section 5.1 shall be binding upon each person or entity which are granted certain rights under this Agreement and the Company. 
  
 4.2 Notices. All notices and other
communications required or permitted hereunder shall be in writing and, except as otherwise noted herein, shall be deemed effectively given (i) upon personal delivery or delivery by nationally recognized courier, (ii) when sent by confirmed
electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, or (iii) five (5) days after having been deposited with the United States Post Office, (by registered or certified mail,
return receipt requested, postage prepaid) addressed (a) if to the Company, at the address set forth on the first page of this Agreement (or at such other address as the Company shall have furnished to the Holders in writing) attention of Chief
Executive Officer and (b) if to a Holder, at the latest address of such person shown on the Company’s records; provided, however, that registered or certified mail shall not be used to effectuate delivery of any such notice under
this Agreement if the party to be notified is located outside of the United States. 
  
 4.3 Descriptive Headings. The descriptive headings herein have been inserted for convenience only and shall not be deemed to
limit or otherwise affect the construction of any provisions hereof. 
  
 4.4 Governing Law. This Agreement shall be governed by and interpreted under the laws of the State of Florida as applied to agreements among Florida residents, made and to be performed entirely within
the State of Florida. 
  
 4.5
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original and all of which shall constitute the same instrument, but only one of which need be produced.

  
 4.6 Expenses. If any action at
law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may
be entitled. 
  

 13. 

 4.7 Successors and Assigns. Except as otherwise expressly provided in this
Agreement, this Agreement shall benefit and bind the successors, assigns, heirs, executors and administrators of the parties to this Agreement. 
  
 4.8 Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with
regard to the subject matter of this Agreement. This Agreement amends, supersedes and replaces in its entirety all other agreements between or among any of the parties with respect to the subject matter hereof. 
  
 4.9 Separability; Severability. Unless
expressly provided in this Agreement, the rights and obligations of each Holder under this Agreement are several and not jointly held with any other Holders. Any invalidity, illegality or limitation on the enforceability of this Agreement with
respect to any Holder shall not affect the validity, legality or enforceability of this Agreement with respect to the other Holders. If any provision of this Agreement is judicially determined to be invalid, illegal or unenforceable, the validity,
legality and enforceability of the remaining provisions shall not be affected or impaired. 
  
 4.10 Stock Splits. All references to numbers of shares in this Agreement shall be appropriately adjusted to reflect any
stock dividend, split, combination or other recapitalization of shares by the Company occurring after the date of this Agreement. 
  
 4.11 Aggregation of Stock. All shares of the Series E Stock held or acquired by affiliated entities or persons shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 14. 

 IN WITNESS WHEREOF, the parties have executed this
Investors’ Rights Agreement on the day and year first set forth above. 
  

			
	 “COMPANY”
  
 ACCENTIA, INC.

		
	By:	 	 
	 	 	 Francis E. O’Donnell, Jr.
 Chief Executive Officer

  

			
	“OSMAN”
		
	By:	 	 
	 	 	 Ronald E. OsmanForm of Series E Subscription Agreement

  
 Exhibit 4.11

  
 SUBSCRIPTION AGREEMENT 
  
 Dear Sirs: 
  
                                       
                               hereby subscribes for
                    (                  
  ) Series E Units with each Unit consisting of one share of authorized but unissued Series E Convertible Preferred Stock (“Series E Preferred”) of Accentia, Inc. (the “Company”) and two warrants each to purchase one
additional share of Series E Preferred under the terms described in the attached warrants (“Series E Warrants”) at a purchase price of $1.00 per Series E Unit for a total purchase price of
                     (the “Subscription Purchase Price”). The Subscription Purchase Price is deemed paid in cash at time of issuance
of the Series E Units. 
  
 2. I understand that the Company
reserves the right to reject, in whole or in part, any offer to subscribe, for any reason whatsoever, and that no subscription may be withdrawn once made. 
  
 3. I understand that once accepted by the Company, will be used by the Company for general working capital, overhead and operating purposes. I further
understand that no assurance can be given as to the Company’s ability to access capital as and when required. 
  
 4. I represent that: (a) my commitment to all investments is reasonable in relation to my net worth; (b) I have the requisite knowledge or have relied
upon the advice of my own counsel, accountants or others, each of whom qualifies as an Investor Representative with regard to all of the considerations involved in making this subscription; (c) I will be acquiring the Units, shares and warrants of
the Company for investment and not with a view for resale or distribution of the Shares; (d) I am aware that the right to transfer the Units, Shares and warrants and the shares of Common Stock into which the shares of Series E Preferred stock may be
converted, is restricted in accordance with state and federal securities laws; (e) I have the financial ability to bear the economic risk of the investment in the Company (including the complete loss of the entire investment), adequate means of
providing for my current and anticipated needs and personal contingencies, and no need for liquidity with respect to my investment in the Company; (f) my overall commitment to investments which are not readily marketable is not disproportionate to
my net worth and my investment in Shares of the Company will not cause such overall commitment to become excessive; (g) I am an “accredited investor” as defined in Regulation D promulgated under the Securities Act; (h) I acknowledge that
the Company will require additional capital and financing and that it does not a binding commitment fro the required capital or financing; (i) the per-share purchase price of the shares of Series E Units was arbitrarily established by the Company
without the benefit of independent appraisal and I may experience substantial dilution to my investment; (j) I understand that the Company may offer preferred stock to strategic investors which may be granted preferences and rights senior and
superior to the shares of Series E Preferred stock; (k) I acknowledge that the Company’s shares of Series E preferred stock and Common Stock are not trading over any recognized exchange or at all, and accordingly, the Shares being purchased
hereunder are considered by me to be non-tradeable and illiquid and no assurance can be given as to when, if at all, its Shares will be traded; (l) substantial additional capital will be required by the Company and its subsidiaries to implement
their respective business objectives. The Company may be unable to raise such required capital on favorable or timely terms or at all. If the Company can raise additional capital 

  

 
it will result in the sale of additional common or preferred stock of the Company, and will result in dilution to the interests of the subscriber hereunder;
and (n) the Company has significant debt including debt and accounts payable to one of its vendors, McKesson Inc., and Harbinger Financial. 
  
 5. I have relied upon my own independent investigation in connection with this subscription. I have had access to all the following information:

  
 (a) All books and financial records of the
Company and its subsidiary; 
  
 (b) All material
contracts and documents relating to the Company and its subsidiary; 
  
 (c) All financial statements of the Company and its subsidiaries; 
  
 (d) An opportunity to question each of the officers, directors, consultants and others affiliated with the Company and its subsidiaries;
and. 
  
 6. I do not require a prospectus or full disclosure
offering or private placement memorandum concerning the Company or its subsidiaries and I am relying upon my right of access to information and documents and right to ask questions in connection with the subscription hereunder. 
  
 7. By reason of my prior business and financial experience, I have the
capacity to protect my own interest in connection with this subscription. The information set forth in this Subscription Agreement is accurate and complete in all respects. Furthermore, I am purchasing the Series E Units described in this
Subscription Agreement with a view not to resale or otherwise distribute same, except in accordance with federal and state securities laws. I expressly represent that I am an “accredited investor” as defined by the rules and regulations
under the Securities Act of 1933 and am a sophisticated and suitable investor for a development and early stage company, which is subject to a high degree of risk. 
  
 8. Section 517.061(11)(a)(5) of the Florida Securities Act provides as follows: 
  
 “When sales are made to five or more persons in this State (i.e.
– Florida), any sale in this State (i.e. – Florida) made pursuant to this subsection is voidable by the purchaser in such sale, either within three (3) days after the first tender of consideration is made by said purchaser to the issuer,
an agent of the issuer or an escrow agent, or within three (3) days after the availability of that privilege as communicated to such purchaser, whichever occurs later.” 
  
 9. In the event that this subscription is accepted, in whole or in part, I request that the Certificates be registered in
the name(s) printed below. Delivery will be made to the address printed below: 
  

			
	Name:
		
	Address:	 	 
		
	 	 	 

  

 - 2 - 

									
	 ACCEPTANCE OF SUBSCRIPTION
	 	 	 	 
	 Accentia, Inc.
	 	 	 	 Subscriber

					
	By:	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 Dated
                    

  

 - 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00078-of-00352.parquet"}]]